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ANALOGUES OF (-)-PICROPODOPHYLLIN,
SYNTHESIS AND USES THEREOF
CROSS-REFERENCE TO RELATED
APPLICATION

This application is a continuation of International Appli
cation PCT/US09/033,416, filed Feb. 6, 2009 and also claims

priority to U.S. Provisional Patent Application Ser. No.
61/027,459, filed Feb. 9, 2008 and U.S. Provisional Patent

10

Application Ser. No. 61/122,945, filed Dec. 16, 2008, the
contents of which are hereby incorporated in their entireties
herein.
GRANT INFORMATION

15

The subject matter of this application was developed at
least in part under National Institutes of Health Grant No.
NIH/1 PO1CAO97403, so that the United States Government

has certain rights herein.
SEQUENCE LISTING

The specification further incorporates by reference the
Sequence Listing submitted herewith via EFS on Feb. 20.
2009. Pursuant to 37 C.F.R.S 1.52(e)(5), the Sequence Listing
textfile, identified as “0700503731.TXT,” is 1,3661 bytes and
was created on Feb. 20, 2009. The Sequence Listing, elec
tronically filed herewith, does not extend beyond the scope of
the specification and thus does not contain new matter.
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1. INTRODUCTION

The invention relates to (-)-picropodophyllin analogues,
methods of synthesizing said analogues and uses thereof. In
certain non-limiting embodiments, the invention provides for
methods of treating cancers using (-)-picropodophyllin ana
logues, including basal-like cancers of the breast.
2. BACKGROUND OF THE INVENTION

The compound (-)-picropodophyllin binds tightly to the
human Insulin-like Growth Factor I Receptor Kinase (IGF1
RK) domain and inhibits its kinase activity. Such binding has
the effect of inhibiting the anti-apoptotic signal pathways that
are associated with IGF1 RK activity. This inhibition tends to
decrease cancer cell growth and may also render cancer cells
more Susceptible to chemotherapy. Importantly, the com
pound, (-)-picropodophyllin, shows exquisite selectivity for
the IGF1 RK over the structurally highly homologous Insulin
Receptor Kinase (IRK) domain, the inhibition of which
would give an undesired diabetes-type phenotype. This selec
tivity could lead to a new class of chemotherapeutic drugs.
At present, there is no drug on the market that acts upon the
IGF1 RK. Development of such a drug is, therefore, an
emerging macromolecular target of great current interest in
the pharmaceutical community.
Human breast cancers have been molecularly classified by
gene expression profiling into three major Subtypes: luminal,
ERBB2+ and basal-like. The luminal cancers are estrogen
receptor-positive (ER+), whereas the cancers of the other two
classes, which either overexpress ERBB2(HER2/NEU) or
exhibit phenotypic features of basal/myoepithelial cells, are
ER-negative (Perou et al., Nature (2000), 406, 747-52: Sorlie
et al., Proc. Natl. Acad. Sci. U.S.A. (2001), 98, 10869-74;
Sorlie et al., Proc. Natl. Acad. Sci. U.S.A. (2003), 100, 8418
23). Basal-like cancers also lack progesterone receptor (PR)
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2
and ERBB2 (ER-/PR-/ERBB2-; “triple negative breast can
cers'), but frequently express EGFR and basal markers, such
as cytokeratins 5/6 and/or 14 and p63 (Nielsen et al., Clin.
Cancer Res. (2004), 10, 5367-74). The basal-like class (15
20% of all breast cancers; recently reviewed by Yehiely et al.,
Trends Mol. Med. (2006), 12, 537-44; Finnegan and Carey,
Future Oncol. (2007),3,55-63; DaSilva et al., J. Clin. Pathol.
(2007), 60, 1328-32) includes high proportions of BRCA1
associated and also medullary and metaplastic Subtypes. The
latter group is heterogeneous and consists of squamous and
spindle cell carcinomas and other forms. Basal cancers
appear to have extremely bad prognosis (Sorlie et al., Proc.
Natl. Acad. Sci. U.S.A. (2001), 98, 10869-74), especially in
the early years of follow-up after diagnosis and treatment,
although this was not clearly evident in some patient cohorts
(Chin et al., Cancer Cell (2006), 10, 529-41). In addition,
these aggressive cancers pose a serious problem to targeted
therapies, considering that the use of antiestrogens in combi
nation with an anti-ERBB2 antibody (trastuzumab) is not an
option, while there is no clear choice for chemotherapeutic
intervention (see, for example, Cleator et al., Lancet Oncol.
(2007), 8, 235-44; Carey et al. Clin. Cancer Res. (2007), 13,
2329-34).
Interestingly, an association between basal cancers and
Kras amplification is now emerging. Ras-family members,
apparently serving overlapping but also distinct cellular func
tions, act as molecular Switches in signaling pathways regu
lating proliferation or apoptosis, and become constitutively
active and, thus, oncogenic by mutation (usually at codons 12,
13 or 61). Although Kras is overall the most frequently
mutated isoform, there is tissue-specificity and variable inci
dence of mutations in Ras tumorigenic action, as different
human tumors harbor different mutant family members. In
contrast to pancreatic ductal adenocarcinoma, in which Kras
mutations (most commonly in codon 12) can be found at
frequencies as high as 90% (Almoguera et al., Cell (1988), 53.
549-54), the incidence of Kras mutations in breast cancer
appears to be low (~7% on average; reported frequencies of
/40, /25, 3/61 and 3/10; Rochlitz et al., Cancer Res. (1989), 49.
357-360; Prosperi et al., Cancer Lett. (1990), 51, 169-74)
Myaikas, et al. Biochem. Biophys. Res. Commun (1998), 251,
609-612: Chen, et al., Cancer Lett., (2005), 229, 115-22). In
human breast cancer cell lines, however, the observed fre
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quency was higher (~13%; 5/40: Hollestelle et al., Mol. Can
cer. Res. (2007), 5, 195-201). Signaling elicited by non-mu
tated, but overexpressed Ras can also collaborate with other
deregulated pathways in tumor progression and invasion
(Clark and Der, Breast Cancer Res. Treat. (1995), 35, 133
44). For example, incomparison with control breast tissue, 11
of 20 breast cancers exhibited a 2- to 6-fold increase in enzy
matically measured Ras activation (relative amount of GTP
bound form; von Lintig et al., Breast Cancer Res. Treat.
(2000), 62, 51-62), while Western analysis indicated that in
~70% of primary breast cancer specimens (n=132) the level
of Ras was higher than in normal breast tissue (Dati et al., Int.
J. Cancer (1991), 47,833-38). Notably, in 56% (9/16) of exam
ined basal-like human breast cancers identified by expression
profiling, the Kras locus was amplified and, thus, overex
pressed (Herschkowitz et al., Genome Biol. (2007), 8, R76).
The IGF signaling system, which is the major determinant
of mammalian organismal growth (Efstratiadis A Int. J. Dev.
Biol. (1998), 42:955-976), has also been implicated in the
pathogenesis of various human cancers (Pollak MN, et al.,
Nat. Rev. Cancer (2004), 4:505-518.), including breast
tumors (Sachdev D and Yee D. J. Mammary Gland Biol Neo
plasia (2006), 11:27-39). A seminal observation, in this
regard, was that cells lacking Igflr, the tyrosine kinase recep
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tormediating the effects of insulin-like growth factors, cannot
be transformed by any one of several tested oncoproteins
(Sell C, et al. Proc. Natl. Acad. Sci. USA (1993), 90:11217
11221; Sell C, et al. Mol. Cell. Biol. (1994), 14: 3604-3612:
Baserga R, Expert Opin. Ther. Targets (2005), 9:753-768).
Signaling through Igflr does not appear to be an oncogenic
component perse, but a crucial prerequisite for tumorigenesis
because, among other actions such as the promotion of cel
lular proliferation by stimulation of the Ras/MAPK/ERK
pathway, it exerts strong PI3 kinase-dependent and indepen
dent antiapoptotic effects that are necessary for tumor growth
(Baserga R, Expert Opin. Ther. Targets (2005), 9:753-768).
Moreover, the IGF system appears to be involved in resistance
to certain anticancer regimes (Ryan P D and Goss P E.
Oncologist (2008), 13:16-24). On the basis of these consid
erations, potential therapeutic approaches for cancer treat
ment involving blocking of IGF signaling with Small mol
ecules or antibodies are currently under development
(Sachdev D and Yee D. J. Mammary Gland Biol Neoplasia
(2006), 11:27-39; Baserga R. Expert Opin. Ther: Targets
(2005), 9:753-768; Ryan P D and Goss P E. Oncologist
(2008), 13:16-24; Garcia-Echeverria C. IDrugs (2006),
9:415-419; Hartog H, et al., Eur: J. Cancer (2007) 43:1895
1904).
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3. SUMMARY OF THE INVENTION

The present invention provides for compounds, composi
tions, methods of making, and methods of using analogues of
(-)-picropodophyllin, as well as a transgenic animal model
and its use for identifying anticancer agents. It is based, at
least in part, on the discoveries that (i) Igflr was overex
pressed in mammary tumors advantageously induced
extremely rapidly by oncogenic Kras in a mouse model, and
(ii) breast-specific genetic ablation of Igflr expression dem
onstrated that the cognate signal transduction pathway is
causally involved in tumorigenesis.
In particular non-limiting embodiments, the present inven
tion provides for methods of treating a cancer in a subject
comprising administering, to the Subject, an effective amount
of an analogue of (-)-picropodophyllin. In particular, non
limiting embodiments, the cancer cells demonstrate a muta
tion in Kras. In a specific, non-limiting embodiment, the
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35
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cancer is a basal-like cancer of the breast.
45

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A-D. Application of a general method for tissue
specific expression of oncoproteins in mice. (A) Inserts (in
pBSK) or two plasmids used for construction of a targeting

50

vector for knock-in of a chosen cDNA into the Eefla locus

("Eeflal cassette'). The first plasmid consists of a splice
acceptor site (0.2 kb), a floxed segment that includes a neo
selectable marker (0.8 kb) linked to a “stop” sequence (SX
pA: triple polyA, 1.5 kb), and a polylinker (multiple cloning
sites; MCS) followed by an additional polyadenylation signal
(pA: 0.25 kb). A chosen cINA is cloned into the MCS, and
then the entire compound insert is excised by digestion with
PacI and AscI and cloned into the corresponding sites of the
second plasmid that provides 5' and 3' homology arms to the
final targeting vector. The engineered PacI and AscI sites
(separated by a PmeI site) have replaced a Spel site in the first
intron of Eefla1. The experiments described herein utilized
an older version of the first plasmid, in which the neogene
was driven by the Pgk promoter. (B) Homologous recombi
nation in ES cells ("knockin': indicated by X symbols) using
a targeting vector that was constructed by inserting into the
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MCS of the Eefla cassette an oncogenic Kras cDNA. A
simplified restriction map and the noncoding and coding
exons of the locus (open or filled rectangles, respectively) are
indicated. Excision of the “floxed’ block from the targeted
allele by Cre-mediated recombination (using in this case a
Wap-cre transgene for specific expression of the recombinase
in mammary glands) allows excision of the “stop” sequence
and consequent Kras transcription driven by the Eefla pro
moter. (C) Molecular analysis. Southern analysis was per
formed using EcoRV-digested DNA that was extracted in the
examples shown either from tails of a wild-type or a trans
genic animal, or from a Kras-induced tumor that developed
after Wap-cre-mediated recombination. Northern analysis
shows that, in addition to the two endogenous Kras mRNAs
which are transcribed from the intact allele in wild-type mam
mary glands (MG), the targeted allele expresses in tumors two
new Kras transcripts (marked by asterisks in the figure).
Western analysis using an antibody recognizing the Kras4B
isoform encoded by Kras indicates that the amount of the
oncoprotein is significantly higher in mammary tumors than
in normal glands. (D) Kaplan-Meier tumor-free mouse Sur
vival curves. The survival of female mice from the day of the
first parturition until the day of detection of palpable Kras
induced tumors is compared between animals carrying the
oncogenic transgene either in the presence of wild-type Igflr
or in a genetic background in which one or both floxed Igfr1
alleles have been conditionally ablated. In mice possessing at
least one intact Igfr1 allele, tumors appear immediately after
a single pregnancy, in contrast to the animals with Igfr1
nullizygous mammary epithelial cells (three pregnancies).
FIG. 2A-C. Histology and immunophenotyping of mam
mary carcinomas. (A) Krasi-induced mouse mammary
tumors exhibit four histopathological forms. The insets in the
H&E-stained sections (first row) show CISs of the corre
sponding invasive carcinomas. For details about the immun
ostaining results, see Example3 and Table 4. (B)Examples of
mouse and human pale breast cancers. A mouse Kras-in
duced pale cell carcinoma exhibits a strong histological simi
larity (H&E staining) with a specimen of human atypical
medullary breast cancer and both tumor types are strongly
positive for Igflr immunostaining. (C) KRAS copy gains in
Some atypical medullary breast cancers with pale cells. The
dual color FISH analysis using KRAS (red/lighter) and chro
mosome 12 centromeric (green/brighter) probes shows that,
in cells from three different human pale breast cancer speci
mens (the right panels are from the same tumor), there are
copy gains of the 12p12.1 region (up to 6 KRAS copies).
FIG. 3A-F. Drug treatment of Kras-induced mammary
carcinomas. Examples of tumor development in mice carry
ing an activated Kras oncogenic transgene, which were
injected either with vehicle (“V”, panels A, C and E) or with
picropodophyllin (“PPP, designated “P” in the figure, panels
B, D, and F). Examination of tumors macroscopically (A, B)
and histologically (C, D) after three weeks of treatment
showed that, in comparison with the controls (A and C.
vehicle), the PPP-treated tumors were dramatically smaller
(B and dotted circles in D). Compared to vehicle (E), admin
istration of PPP for 3 days increased -9-fold the level of
apoptosis detected in the pale component, as assayed by
activated caspase 3 immunohistochemistry (brown staining).
Scale bar-1.0 cm (A and B); scale bar 5.0 mm (C and D).
Original magnifications: x20 (C and D); x400 (E and F).
FIG. 4A-F. Effects of PPP administration for 3 weeks (P:
panels B, D and F) compared to vehicle injection (V, panels A,
C and E) on the components of Kras-induced carcinomas.
The PPP treatment diminishes the size of pale cell tumors (B.
dotted circles) and results in extensive keratinization (D) and
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Vaculolation (D inset) of the squamous component. Original
magnifications: x200 (A-D); x40 (D inset); x400 (E. F).
FIG. 5A-G. Similarity of mouse and human pale breast
cancers. A mouse Kras-induced pale cell carcinoma (A)
exhibits a strong histological similarity (H&E staining) with
an example of a human atypical medullary breast cancer (C)
and both tumor types (B and D, respectively) are strongly
positive for Igflr immunostaining. The dual color FISH
analysis using KRAS (red) and chromosome 12 centromeric
(green) probes (panels E, F and G: individual cells from three
different human pale breast cancer specimens like the one in
C) shows amplification of the 12p12.1 region (up to six
KRAS copies).
FIG. 6. Immunophenotyping of Kras-induced mouse
mammary carcinomas (Part II).
FIG. 7. Hierarchical clustering of genes (rows) and speci
mens (columns). The dendrogram shown (derived by unsu
pervised analysis using CYG WIN software) reveals that there
is clear discrimination in gene-expression patterns between
normal (WT) mammary glands and tumor specimens strati
fied according to the degree of their enrichment in one of the
three basal-like components (sarcomatous, SRC, squamous,
SCC; and pale, PCC). A scale is shown on the right.
FIG. 8A-C. In vitro inhibition of Igflr action. Representa
tive experiments of pharmacological inhibition of IGF1R in
MDA-MB-231 cells by picropodophyllin (A) or by IGF1R
knockdown using a dominant-negative construct (B) or
siRNA (C). The absorbance (mean values+S.E.M.) reflects
cell numbers estimated from duplicate samples using the
MTT assay (see Experimental Procedures). (A) MDA-MB
231 cells were seeded in 24-well plates at 10% confluence
(day 0) and treated with vehicle (DMSO: final concentration
0.1%) or PPP dissolved in DMSO (final concentration 500
nM). (B) Plasmid 486Stop (encoding dominant-negative
IGF1R) or a control plasmid (pcDNA3) were introduced in
MDA-MB-231 cells by nucleofection following the manu
facturer's protocol (1.5 g of plasmid DNA per 106 cells;
Amaxa Biosystems). The same method was used to introduce
into these cells a 19-bp RNA duplex (R4) targeting IGR1R
mRNA or a scrambled control duplex (Scra; see SI Materials
and Methods, for details). The efficiency of nucleofection
under our conditions (estimated by adding to the samples a
GFP-expressing plasmid) was ~60%.
FIG. 9. Example of FACS Analysis of Mammary Cell
Suspensions. Cells were isolated from normal mammary
glands of parous animals or from invasive mammary carci
nomas that developed in mice carrying a Kras oncogenic
transgene. Flow-sorting of progenitor cell populations was
performed as described (Stingl, J. et al. Nature (2006), 439:
993-997). The MRU fraction (mammary repopulation units)
is enriched in mammary stem cells, whereas the Ma-CFC
fraction (mammary colony-forming cells) is enriched in

6
tially, while the intensity of signal in PCC and SRC was
variable and did not involve all cells.
5. DETAILED DESCRIPTION OF THE
INVENTION
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Both markers were found co-localized in the basement mem

Thus, (-)-podophyllotoxin, the C-2-epimer of (-)-pi
cropodophyllin, features a structurally distinct trans-fused
lactone in the D-ring. (-)-Podophyllotoxin acts as an anti
mitiotic and does so by binding tightly to tubulin, thereby
preventing its polymerization in spindle formation. The struc
ture of the (-)-podophyllotoxin-tubulin complex has been
established by X-ray crystallography.
If one inverts the C-4 center one arrives at the family of
epipodophyllotoxins i.e. epimers at both C-2 and C-4 of
(-)-picropodophyllin, including etoposide, teniposide, and
TOP-53. These compounds act by binding to the enzyme
topoisomerase II and inhibiting the religation step along the
enzymatic reaction coordinate. This leads to a build up of a
covalent enzyme-DNA complex that serves as a cellular sig
nal, triggering apoptosis.
Thus, while members of all three of these lignan families
are of interest as potential medicinal agents, if one wishes to
develop chemotherapeutics that target the IGF1 RK, control
of stereochemistry is important, and represents an important
feature of this invention.

brane of the myopithelial layer in normal glands. Itgb1 was
also present in the basolateral, but not the luminal aspect of

The natural product (-)-picropodophyllin is shown above
as 1.

luminal cells. This distribution was maintained in microaci

nar adenocarcinomas, but only for Itgb1, whereas the basal
like forms had altered patterns. Thus, all SCC cells exhibited
intense labeling for both markers co-localized circumferen

lower.

An aspect of the invention is directed to analogues and a
method for the synthesis of analogues of the natural product
(-)-picropodophyllin with control of both absolute and rela
tive stereochemistry. Absolute and relative stereochemistry
are important for biological activity in lignans.

luminal cell precursors. Ma-CFCs are CD24" CD49f",
whereas MRUs are CD24" CD49f's". The percentages of
cells in these populations are indicated.
FIG. 10. Localization of integrins C6 (CD49f) and B1
(CD29). The distribution of Itgaé and Itgb1 in normal mam
mary glands and in the four histopathological forms of Kras
induced invasive carcinomas was determined by double
immunofluorescence using the antibodies listed in Table 9.

The invention provides inhibitors of IGF1RK as well as
methods of synthesizing the inhibitors and using them thera
peutically. As therapeutics, these Small molecules have
advantages over antibodies, including circumventing pos
sible immune responses associated with the latter, as well as
permitting oral administration and potentially increasing bio
logical half-life. Production cost is also likely to be much

65

Aspects of the present invention are directed to analogues
of (-)-picropodophyllin having modified E-rings as shown
below in formula I.
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aspects, X, X', Y.Y. and Z are hydrogen, methyl, or methoxy
with the proviso that when X and X’ are H.Y.Y', and Z cannot
all be methoxy.
In further aspects, the present invention is directed to (-)picropodophyllin analogues with modified E-rings as shown
below.

10

15

Many types of substitutents are available for ring Edue to
the late addition of ring E during synthesis of the compounds.
X, X'.Y.Y. and Zare ring E substituents and X, X', Y.Y. and
Z may be independently hydrogen; deuterium; tritium; a
C-C saturated or unsaturated, alkyl or cycloalkyl group; a
hydroxyl group; an ether-protected hydroxyl group bearing a
C-C Saturated or unsaturated alkyl or cyclic alkyl group; a
carboxylate ester-protected hydroxyl group derived from a
C-C Saturated or unsaturated, cyclic or acyclic, carboxylic
acid; a hydroxyl group protected as a phosphate mono-, di- or
triester, the di-, or triester having C-C Saturated or unsatur
ated alkyl group(s): a C-C alkoxy, a C-C alkoxy, a phos
phonate mono- or diester-protected hydroxyl group derived
from a C-C saturated or unsaturated, cyclic oracyclic, phos
phonic acid wherein the diester also contains a C-C Satu
rated or unsaturated alkyl group; a phosphinate ester-pro
tected hydroxyl group derived from a phosphinic acid bearing
two C-C Saturated or unsaturated, cyclic or acyclic, alkyl
groups; a hydroxyl group protected as a Sulfate mono- or
diester bearing a C-C Saturated or unsaturated alkyl group;
a hydroxyl group protected as a Sulfonate ester derived from
a Sulfonic acid bearing a C-C Saturated or unsaturated,
cyclic or acyclic, alkyl group; an amino group; a primary or
secondary amine bearing 1 to 2 C-C Saturated or unsatur
ated alkyl group(s), respectively; a carboxamide-protected,
unsubstituted or primary amine bearing a C-C Saturated or
unsaturated alkyl group; an amino group derived from a
C-C Saturated or unsaturated, cyclic or acyclic, carboxylic
acid; a carboxylic acid; a carboxylate ester bearing a C-C,
saturated or unsaturated alkyl group; a phosphonic acid; a
phosphonate mono- or diester bearing 1 to 2 C-C Saturated
or unsaturated alkyl group(s), respectively; a phosphinic acid
having a C-C saturated or unsaturated, cyclic or acyclic,
alkyl group or ester bearing a C-C Saturated or unsaturated
alkyl group; a formyl group; an acetyl group; a benzoyl
group; a carboxamide group derived from ammonia or from a
primary or secondary amine bearing 1 to 2 C-C Saturated or
unsaturated alkyl group(S), respectively; a sulfhydryl group; a
thioether bearing a C-C Saturated or unsaturated, cyclic or
acyclic, alkyl group; a Sulfonic acid, a Sulfonate ester bearing
a C-C Saturated or unsaturated alkyl group; an alkylsulfonyl
group bearing a C-C Saturated or unsaturated, cyclic or
acyclic, alkyl group; a phenylsulfonyl group; a Sulfoxide
bearing a C-C Saturated or unsaturated, cyclic or acyclic,
alkyl group; a phenylsulfoxide; a phenylseleno group; a phe
nylselenoxide; an azide; a halogen; a cyano group; a nitro
group; a nitroso group; a diazonium group; or a trifluorom
ethyl group with the proviso that when X and X’ are H.Y.Y",
and Z cannot all be methoxy.
In further aspects, X, X, Y, Y and Z are independently
hydrogen, a C-C alkyl or C-C alkoxy group. In further

Wherein
25

30

35

40

45

50

(1) X, X, Y, Y-H, and Z=OCH (compound 19, below)
(2) X, X, Y, Z=H, and Y=OCH:
(3) X, X, Y, Z=H, and Y—OCH (compound 18, below)
(4) X, X", Y-H, and Y, Z=OCH:
(5) X, X', Y=H, and Y, Z=OCH (compound 20, below)
(6) X, X', Z=H, and Y.Y'—OCH (compound 21, below)
(7) X, X, Y, Y-H, and Z=CH,
(8) X, X, Y, Y-H, and Z=CH, C(4)-epimer-4-epi-pi
cropodophyllin analaogue)
The present invention is also directed to enantiomerically
enriched compounds which do not occur naturally and are not
readily available from (-)-picropodophyllin. Enantiomeri
cally enriched means that the enantiomeric ratio is at least
95:5, preferably at least 97:3, prior to recrystallization.
The present compounds may be prepared by first preparing
a compound of formula (a) by any suitable means such as
starting from readily available piperonal, utilizing (i) bromi
nation, (ii) acetalization and (iii) installation of a hydroxym
ethyl group (halogen/metal exchange and aryllithium trap
ping with paraformaldehyde).
In the presence of acetic acid, formula (a) cyclizes and,
upon losing two molecules of MeCH, transiently provides the
highly reactive isobenzofuran (b), which reacts, in situ, via a
Diels-Alder reaction with DMAD (dimethyl acetylenedicar
boxylate) to form Diels-Alder adduct (c).
OMe
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OMe ----->
OH

O
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(b)
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ing the (-)-picropodophyllin core in a single operation,
immediately following the stereocontrolled installation of
ring E.
Aldehyde oxidation proceeds Smoothly under Lindgren
conditions (NaClO, as oxidant) to give (g). The efficient
retro-Michael ring-opening of (f) unveils the (methylene
dioxy)cinnamyl system as the vehicle for late installation of
ring E.

-continued
O
O

OMe

A.

D

O

OMe
O

(c)

10

(g)
R10

Diels-Alder adduct (c) can be selectively hydrogenated,
reduced to the diol with LiAlH4 and acetylated to provide
meso diacetate (d).

O
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CHOR

O
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R" is a C protecting group such as a triethylsilyl-protect

O

K

OH

O

OAc
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The achiral and symmetrical system bearing all carbons of
the target cyclolignan A-D rings is efficiently desymmetrized
with porcine pancreatic lipase (PPL) to produce (e) in syn
thetically useful enantiopurity level.
The compound of formula (e) is subjected to silylation,
deacetylation, and oxidation to produce a compound of for
mula (f) without loss of optical activity. Sillylation occurs with

a silylating agent, RX, including but not limited to TIPSC1

(triisopropylsilyl chloride), TBDMSC1 (tert-butyldimethylsi
lyl chloride), and TBDPSC1 (tert-butyldiphenylsilyl chlo
ride), in the presence of an appropriate base Such as imidazole
or NEts. Deacetylation is carried out under standard condi
tions (e.g. EtO, NaHCO, or KCO, MeOH or Na, MeOH or
NH, MeOH.) The aldehyde is then oxidized under mild
two-electron oxidation conditions (e.g. Swernor Moffattoxi
dation (DMSO as oxidant), Ley oxidation (TPAP tetrapro
pylammonium perrhuthenate as oxidant) or Dess-Martin oxi
dation (Dess-Martin periodinane as oxidant.))
O

ing group.
The compound of formula (g) is converted to a compound
of formula (h) by transformation of the carboxylic acid into an
acyl oxazolidinone functionality. This requires carboxyl acti
Vation (e.g. with carbonyl diimidazole) and then condensa
tion with a metalated oxazolidinone to give (h).
(h)

30

CHOR

( \,
35

O

Y
O

The Ering is introduced to the compound of formula (h) to

form a compound of formula (I) by Cu'-mediated conjugate
40

addition of RMgBr at a temperature of -10 to 10° C.
(i)

45

CHOR
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50
Her

O

CHOH

(f)

R is a silyl protecting group such as a triisopropylsilyl
protecting group.
The compound of formula (f) is converted to a compound
of formula (g) by retro-Michael ring opening and protection
of the C OH followed by aldehyde oxidation. The ring
opening occurs under typical Michael addition conditions
(such as NaOMe and MeOH). The protection step must be
carried out under neutral to basic conditions (to avoid aroma
tization). Use of a silyl (such as TES=triethylsilyl)ether pro
tecting group for the C-4 hydroxyl is an advantageous feature
of the present invention. This sets the stage for an efficient
desilylative lactonization at the close of the synthesis, unveil

55

The compound of formula (i) is converted to a compound
of formula () by desilylative lactonization by heating with a
fluoride source and cyclization to produce the corresponding
lactone;
()
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Non-limiting examples of Such syntheses are provided in
Section 6. Example 1, below, the details of which are incor
porated by reference in their entirety into this Section 5.
Further aspects of the invention are directed to (-)-pi
cropodophyllin analogues as shown below.

12
Y-H, and Y, Z=OCH; (5) X, X,Y-H, and Y, Z–OCH:
(6) X, X, Z=H, and Y, Y=OCH; X, X, Y, Y-H, and
Z=CH and (8)X, X,Y, Y-H, and Z=CH, C(4)-epimer
4-epi-picropodophyllin analaogue).
5

II
10

O

15

wherein X, X,Y.Y', and Zare defined as above; R' may be
oxo. —OH, -OCH —OCHs —OCH7, -OCH,
–OCH-CH=CH,
OCHPh,
OCHCH-NH2,
OCOH,
OCOCH,
OCH-OH,
OCHOH,
—OCHOH, -OCHOH, or a glycoside. In specific, non

25

limiting embodiments, R' may be oxo, OH, OCH,

—OCHs

–OCHPh,

—OCH7,

OCH

OCHCH-NH,

—OCH-CH=CH,

OCOH, OCOCH,

30

–OCHOH, OCHOH, - OCHOH, - OCH-OH, or a

glycoside and X, X, Y, Y and Z are selected from the group
consisting of (1) X, X,Y.Y'—H, and Z—OCH; (2) X, X,Y,
Z—H, andY—OCH; (3) X, X,Y,Z=H, andY—OCH; (4)
XX,Y—H, and Y, Z=OCH; (5) X,X,Y-H, and Y,
Z—OCH; (6) X, X', Z=H, and Y, Y-OCH; X, X, Y,
Y—H, and Z=CH, and (8) X, X, Y, Y-H, and Z=CH,
C(4)-epimer-4-epi-picropodophyllin analaogue).
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may be independently oxo. —OH, -OCH —OCHs.
–OCH, OCH, OCH-CH=CH, OCHPh.
OCHCH-NH
OCOH, OCOCH,
OCHOH,
OCHOH, - OCHOH, - OCHOH, or a glycoside. In

specific, non-limiting embodiments, R' and R may be inde

pendently oxo, —OH, -OCH —OCHs —OCH7.
—OCH,
–OCH-CH=CH,
OCHPh.
–OCHCH-NH,
OCOH, OCOCH, OCHOH,
OCHOH, - OCHOH, - OCHOH, or a glycoside, and
X, X'.Y.Y. and Zare selected from the group consisting of (1)
X, X, Y, Y-H, and Z=OCH; (2) X, X, Y, Z=H, and
Y—OCH; (3) X, X, Y, Z=H, and Y—OCH; (4) X, X',

porated herein by reference.
Preferred, non-limiting embodiments of the invention
include 5'-Didemethoxy-(-)-picropodophyllin (Compound
18), 3',5'-Didemethoxy-(-)-picropodophyllin (Compound
19), 5'-Demethoxy-(-)-picropodophyllin (Compound 20),
and 4'-Demethoxy-(-)-picropodophyllin (Compound 21),
the syntheses of which are described in the working
examples.
The effects of the compounds described above on activities
of IGF1R can be determined in in vitro and in vivo assays, as
described in the Examples below. Example 2 describes a
method of monitoring the effect of compounds on cell
growth. Inhibition of kinase activity of the IGF1R can be
measured by any means known in the art. The kinase domain
of the receptor is available from Upstate Biotechnology.
In one embodiment, a cell line is used to assay the effects of
these compounds on activities of IGF1R, for example, a
murine breast cancer cell line derived from Kras mice. In

one embodiment, the cell line is placed in a multi-well-plate,
including, but not limited to a 24-well plate, and a 96-well
plate. In one embodiment, cells contained in a Subset of wells
are treated with a substrate, for example, a Substrate used in a
calorimetric metabolic assay that reflects cell density, for
example, MTT (Thiazol Blue Tetrazolium), and cells in
another subset of wells are treated with an IGF1R inhibitor,
for example, cyclolignan picropodophyllin (PPP), or the
compound(s). The effectiveness of these compounds on
activities of IGF1R is compared with that of a known IGF1R
inhibitor, for example, PPP.
The Kras mouse is a suitable in vivo model in which to test

III

wherein X, X', Y.Y', and Zare defined as above; RandR

Examples of suitable R' and R substituents include the
substituents disclosed in U.S. Pat. Nos. 5,132,322; 5,300,500;
5,332,811: 5,541,223; and 6,051,721 which are each incor
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the effect of IGF1RK inhibitors on tumor growth (see
Examples 3 and 4). The Kras mouse overexpresses a Kras2
gene carrying the oncogenic Substitution G12D. The gene has
been knocked-in into the highly and ubiquitously expressed
locus Eefla. Cre-mediated removal of a STOP sequence
residing upstream from the Kras cDNA allows for its tissue
specific expression. Mice in which the oncogene is activated
in the mammary epithelium by use of the WAPcre line
develop tumors very rapidly (as early as 2 days upon partu
rition; T50–9 days). Moreover, these tumors display high
heterogeneity in histopathology. Four major patterns of inva
sive carcinoma were detected (well differentiated glandular
adenocarcinoma (Dunn A and B Tumors), pale cell carci
noma, squamous cell carcinoma and spindle cell (sarcoma
tous) carcinoma). In addition, histopathological characteriza
tion of the tumors showed that, with the exception of the
glandular adenocarcinoma, these tumors express basal mark
ers and share great similarities in expression profiles with
human and mouse basal-like breast cancers. Expression pro
file analysis and immunophenotyping showed that the IGF1R
was significantly overexpressed in the Kras-induced neo
plasms. This is believed to be the first description of a mouse
model in which a malignant neoplasm is induced by a single
tumorigenic stimulus in one step without a requirement for
secondary oncogenic events, as evidenced by the rapidity of
tumor development. This unexpected observation can be
attributed to the abnormally high expression levels of a pow
erful oncogene.
Accordingly, in one set of embodiments, the present inven
tion provides for a system and a method for producing a
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transgenic animal model of a human tumor, wherein a tumor
in the transgenic animal is induced by expression of an onco
gene operably linked to a Eefla (for Eukaryotic translation
Elongation Factor 1 Alpha 1) promoter (e.g., the endogenous
promoter), and expression of the oncogene is triggered by
excision of a “stop’ (transcription termination) signal by
Cre-mediated recombination. The oncogene may be intro
duced into the Eefla 1 locus by “knockin' technology into an
area of the gene Such that, after transcription, it will be trans
lated. In one embodiment, a cDNA encoding the oncogene is
inserted into an intron as part of a construct having a splice
acceptor site (i) downstream of a “floxed’ stop signal and (ii)
upstream of the cDNA coding sequence (to prevent the con
struct sequence being spliced out from the mRNA precursor
and lost during mRNA maturation); preferably, the construct
is inserted into the first intron. However, the present invention
also envisions inserting a construct comprising the cDNA
encoding the oncogene into an exon of the Eefla locus,
although this would be less desirable. In various embodi
ments of the invention, the oncogene may be any oncogene
known in the art, including but not limited to Kras and acti
Vating mutations thereof (e.g., at codons 12, 13, or 61, e.g.,
G12D), Hras, c-myc, Her2/neu, Src, Wnt 1, PI3 kinase, etc.
In non-limiting set of embodiments of the invention, an
Eeflal cassette may be prepared comprising (from upstream
to downstream) (i) a 5' arm homologous to the Eeflal site
being targeted; (ii) a splice-acceptor site; (iii) a loXP site; (iv)
a transcription termination signal (e.g., a multiple signal Serv
ing, before its removal, as a block “STOP’’ sequence); (v) a
loXP site; (vi) a multiple cloning site; (vii) a polyadenylation
signal and (viii) a 3' arm homologous to the Eefla 1 locus
targeted, further comprising a nucleic acid encoding a select
able marker (e.g., neo), positioned upstream of the transcrip
tion termination signal. Any gene of interest, including but
not limited to an oncogene Such as Kras or an activated form
thereof (designated “Kras' herein), may be inserted into the
multiple cloning site. A non-limiting example of such a con
struct is shown in FIGS. 1A and 1B. ES cells may be elec
troporated with this cassette, expression of the selectable
marker may be used to select for targeted cells, and integra
tion at the correct locus may be confirmed by standard tech
niques. An ES cell carrying the desired "knockin' transgene
may then be used to produce a first transgenic animal that can
transmit the genetic modification to its progeny.
According to the present invention, a first transgenic ani
mal carrying an Eeflal cassette described in the preceding
paragraph may be mated with a second transgenic animal
carrying a transgene comprising a Cre-gene operably linked
to a promoter, where the promoter is either active or shows
increased activity in a specific tissue, and/or at a specific
developmental stage, and or under certain conditions (e.g.,
during late pregnancy and lactation, or in response to an agent
Such as tetracycline or tamoxifen). Thus, an initially dormant
oncogene present in the Eeflal cassette may be conditionally
activated. In progeny animals carrying both the Eeflal cas
sette and the Cre transgene, the nature of the Cre-linked
promoter determines the site and timing of oncogene expres
Sion, as Cre expression results in removal of the stop tran
Scription signal and, consequently, permits transcription of
the oncogene. Accordingly, the present invention may be used
to produce tumors in specific tissues; a Cre gene operably
linked to a pancreas-specific promoter Such as Pdx1 may be
used to induce pancreatic cancer in a progeny animal; a Cre
cDNA operably linked to a colon-specific promoter such as
Villin may be used to produce a colon cancer in a progeny
animal, and so forth. In a specific, non-limiting embodiment
to develop an animal model system for breast cancer (luminal

10

15

14
type, ERBB2+ type, and (in particular) basal-like), the second
transgenic animal may carry a transgene in which a Cre gene
is operably linked to a milk whey acidic protein (“Wap')
promoter, so that a selected progeny animal for use as a model
of breast cancer carries the Eefla 1 cassette and the Wap-Cre
transgenes. Oncogene expression may be induced in Such an
animal by lactation. FIG. 1B depicts the targeted Eefla 1 locus
after Cre-mediated excision of the termination signal. As
reported in the working example below, where the oncogene
is an activated Kras gene, a tumor may be produced in as
short a time as 2 days following parturition.
The transgenic animal produced according to the invention
may be any non-human species of animal. In a preferred,
non-limiting embodiment, the transgenic animal is a mouse.
In a related set of non-limiting embodiments, the present
invention provides for a cell line derived from a transgenic
animal model, as described above, where the cell line is

produced from a cancerous cell of the transgenic animal
model in which the oncogene transgene is being expressed. In
a specific, non-limiting example, the cell line is prepared from
a mammary tumor of a transgenic mouse expressing activated
Kras under transcriptional control of the Eefla 1 promoter,
as described in FIG. 1B.
25
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In a further related set of non-limiting embodiments, the
present invention provides for a transgenic animal carrying,
in addition to Eeflal cassette and promoter/Cretransgenes as
described above, a heterozygous mutation of IgflR.
In various non-limiting embodiments, the present inven
tion provides for use of a transgenic animal model of a human
tumor, as described above, to identify an agent useful for the
treatment of said human tumor, where the nature of the tumor
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is determined by the site of expression of the oncogenic
transgene. In various non-limiting embodiments, the trans
genic animal model may be a model for breast cancer, or for
pancreatic cancer, or for colon cancer, or for lung cancer, or
for skin cancer, or for prostate cancer. In a specific, non
limiting embodiment, the transgenic animal model is a model
of basal cell type breast cancer.
Accordingly, the present invention provides for a method
comprising (i) providing a transgenic animal, as described
above, carrying a Eeflal cassette comprising a Cre-activat
able oncogene and a transgene comprising Cre under the
control of a promoter permitting conditional activation of Cre
expression; (ii) providing a condition which results in the
expression of Cre in the animal with consequent expression of
the oncogene; (iii) administering, to said animal, a test agent;
and (iv) determining the effect of the test agent on the growth
and/or histology of a tumor in the tissue in which the onco
gene is activated by Cre and expressed, and/or determining
clinical markers associated with malignancy and/or deter
mining the survival of the animal, where the ability of the test
agent to inhibit growth of the tumor, or increase differentia
tion in the histology of the tumor, or decrease one or more
clinical marker of malignancy, or increase the Survival of the
animal, indicates that the test agent may be used to treat the
human tumor being modeled, and may be advanced to human
clinical trials. Step (iv) may be achieved by providing a sec
ond transgenic animal essentially genetically identical to the
animal of step (i), providing essentially the same condition as
provided in step (ii), and then determining tumor growth
and/or histology and/or clinical markers associated with
malignancy and/or Survival in the second animal, which is not
administered the test agent and serves as a negative control
and comparing the results with those obtained with the trans
genic animal that had received the test agent. Multiple ani
mals may be administered different dosages of test agent to
evaluate dose/benefit effect. Clinical markers of malignancy
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include, but are not limited to, weight of the animal, as well as
features associated with the tumor resulting from oncogene
expression (for example, a mammary tumor is readily pal
pable). In preferred non-limiting embodiments, the test agent
is a picropodophyllin analogue, Such as, but not limited to,
those described herein, or another test agent which is an Igflr
inhibitor. Analogous experiments may be performed using a
cell line prepared from the transgenic animal expressing the
oncogene, wherein, after administration of test agent, fea
tures of the malignant phenotype, including rate of prolifera
tion, contact inhibition, ability to grow in Softagar, and mark
ers of apoptosis, may be measured (and where preferably
these features are compared between cells exposed to the test
agent and control cells which are not).
In further non-limiting embodiments, the present invention
provides for a method of treating a cancer, e.g. a cancer for
which intact signaling of Igflr is related to tumor develop
ment and/or Kras is activated, amplified and/or mutated,
comprising administering, to a Subject in need of such treat
ment, an effective amount of a picropodophyllin analogue as
described herein. Igflr-related cancers include, but are not
limited to breast cancer, prostate cancer, glioblastoma, colon
cancer, liver cancer, and ovarian cancer. Optionally, said Sub
ject may further be administered a dose of a second cancer
therapeutic agent, for example, but not limited to, an epider
mal growth factor receptor inhibitor such as erlotinib, a Raff
neoangiogenesis inhibitor Such as Sorafenib, or other agent

16
Said picrodophyllin and/or analogue thereof may be
administered by any route known in the art, including but not
limited to, local application at tumor site or at site of tumor
excision, intravenous administration, intraarterial adminis

tration, intraperitoneal administration, intrathecal adminis
tration, intraventricular administration, intramuscular admin
istration, Subcutaneous administration, oral administration,
10

IGF1RK inhibitors of the invention can be formulated as
15

at least one IGF1RK inhibitor of the invention mixed with
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results in a concentration local to the cancer of between about

200 nMandabout 800 nM. In specific, non-limiting embodi
ments, the analogue is compound 18 or compound 21 in an
amount that, when administered, results in a concentration
local to the cancer of between about 200 nM and about 800
nM or about 300-600 nM or about 400-500 nM.

pharmaceuticals using methods well known in the art. Phar
maceutical formulations of the invention typically comprise
pharmaceutically acceptable carrier. Preferably the solutions
are sterile and non-pyrogenic. Compounds of the invention
can be formulated for parental administration by a variety of
routes, including by mouth, by injection (e.g., by bolus injec
tion), or by infusion.

known in the art.

In still further, non-limiting embodiments, the present
invention provides for a method of treating basal like breast
cancer, comprising administering, to a human Subject diag
nosed as having basal like breast cancer, an effective amount
of picropodophyllin oran analogue thereof, including, but not
limited to, a picropodophyllin analogue as set forth herein.
Optionally, said subject may further be administered a dose of
a second cancer therapeutic agent, for example, but not lim
ited to, an epidermal growth factor receptor inhibitor Such as
erlotinib, a Rafineoangiogenesis inhibitor Such as Sorafenib,
or other agent known in the art. In specific, non-limiting
examples, said basal likebreast cancer has a phenotype which
is estrogen receptor negative, progesterone receptor negative,
and ERBB2 negative. In further specific, non-limiting
examples, said basal-like breast cancer has a phenotype
which includes one or more of the following: epidermal
growth factor receptor positive, cytokeratin 5 positive, cytok
eratin 6 positive cytokeratin 14 positive, and/or pG3 positive.
In specific, non-limiting embodiments of the invention, an
effective amount of picropodophyllin oran analogue thereof,
for use in methods of treatment as described above, may be
between about 30 mg/kg and 80 mg/kg, and may be adjusted
to optimize effectiveness using standard pharmaceutical tech
niques. In those specific non-limiting embodiments where
erlotinib is added, the dose may be, for example and not by
limitation, between about 25 mg/day and 200 mg/day, or
between about 50 mg/day and 150 mg/day, for a treatment
interval between about 1 day and until treatment is deemed
Successful or adverse effects prevent its continuation. In spe
cific, non-limiting embodiments, the amount administered

topical administration, etc. In one specific non-limiting
embodiment the picropodophyllin analogue is compound 18
herein. In another specific non-limiting embodiment the
picropodophyllin analogue is compound 21 herein.

65

IGF1RK inhibitors of the invention can be administered to

patient, either alone or in pharmaceutical compositions where
they are mixed with suitable carriers or excipient(s) at doses
to inhibit cancer cell growth as a single agent. IGF1RKinhibi
tors of the invention may also make cancer cells more Vul
nerable to treatment with other agents and therefore can be
used to Supplement standard chemotherapy regimens, such as
"CHOP therapy (e.g., the use of combination of drugs such
as Cyclophosphamide, Doxorubicin Hydrochloride. Oncavin
Vincristine and Prednisone) for a variety of cancers. Related
members of each family may be substituted for an individual
component in this combination, and a Subset of these agents
may also be used. IGF1RK inhibitors of the invention can be
administered simultaneously or sequentially with a variety of
chemotherapeutic agents, including but not limited to meth
otrexate, cis-platin and 5-fluorouracil.
For example, IGF1RK inhibitors such as picropodophyllin
analogues of the invention can be used in targeted therapy for
the following cancers, either alone or in combination with any
of the following drugs:
Breast HERCEPTINR) and/or taxol, epothilone, letro
Zole (e.g., FEMARAR), anastrozole (e.g., ARIMI
DEX), tamoxifen
Ovarian taxol

Prostate bicalutamide (e.g., Casodex)
Pancreatic gemcitabine
Non-Hodgkins Lymphoma—RITUXANR)
Multiple Myeloma—bortezomide (e.g., VELCADER)
Lung Cancer topotecan (e.g., HYCAMTINR), Etopo
side, Tarceva (Genentech)
Testicular—etoposide
(e.g.,
ETOPOPHOSR),
VEPESIDR)
Skin imiquimod (e.g., Aldara)
Colorectal—capecitabine (e.g., XELODAR), irinotecan
e.g., CAMPTOR), Epothilone
Myeloid Leukemia GLEEVECR)
The invention will be further described by reference to the
following examples. These examples should not be construed
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in any way as limiting the invention to anything less than that
6.EXAMPLE1

18
mol), and the mixture was stirred for 2 h at 80° C. Excess
DMAD was removed by vacuum distillation, and flash chro
matography (30% EtOAc/hexanes) gave 3 (56.4g, 90%) as a
yellow solid. On a smaller scale, 2 (5.53 g, 24.1 mmol) gave

Synthesis

CDC1) & 3.79 (s, 6H), 5.86 (s. 2H), 5.90 (d.J=1 Hz, 1H), 5.95

which is disclosed or which could have been obvious to

anyone skilled in the art.

3 in 92% yield (13.6 g):mp 117-119°C.; H NMR (300 MHz,

(d. J=1 Hz, 1H), 6.95 (s. 2H); 'C NMR (125 MHz, CDC1) &
53.0, 85.7, 102.2, 105.2, 1414, 146.2, 152.5, 163.5. Anal.

(1)

OMe

10

Calculated for CHO,: C, 59.21; H, 3.98. Found: C, 59.27:
H, 4.11.

O

{O
O

(4)
O
15

Br

Bromoacetyl 1 was synthesized by bromination (Conrad,
P. C. et al. J. Org. Chem., 1987, 52,586-591) and subsequent
acetalization of piperonal (Keay, B. etal. Can. J. Chem. 1983,
61, 1987-1995.)

COMe

Dimethyl meso-(1R,2S*,3R*,4S*)-1,4-Epoxy-6,7methylenedioxy-1,2,3,4-tetrahydro-2.3naphthalene
dicarboxylate (4)

(2)

OMe

25

IBF Diels-Alder product3 (43.2g, 0.14 mol) was dissolved
in EtOAc (300 mL), and 10% Pd/C (1.5 g) was added. The
reaction mixture was hydrogenated at 48 psi for 6 h. The
reaction mixture was filtered through Celite and concentrated

O

{ occ
O

{ O

COMe

OH

30

to give 4 as a white solid: mp 96-99° C.; H NMR (300 MHz,

CDC1) & 3.53 (s, 6H), 3.61 (dd, J=2.3 Hz, 2H), 5.41 (dd.
J=2.3 Hz, 2H), 5.92 (d. J=2 Hz, 1H), 5.96 (d. J=1 Hz, 1H),

4-(Dimethoxy)methyl-5-hydroxymethyl(1.2-methyl
enedioxy)benzene (2)

6.82 (s. 2H); 'CNMR (125MHz, CDC1,) & 48.3, 52.3,81.5,

101.9, 103.9, 137.2, 147.5, 170.5. Anal. Calculated for
35

To a solution of bromoacetal 1 (10.0 g, 36.3 mmol) in THF
(100 mL) at -78°C. was added n-Bulli (25.0 mL, 40.6 mmol.
1.6 M in hexanes) dropwise via Syringe. The Solution was
stirred for 1 h at 0°C. and a suspension of paraformaldehyde
(3.30 g, 36.7 mmol) in THF (60 mL) was added via cannula.
The reaction was warmed to room temperature, stirred for 2 h,
and then quenched with HO/EtO. The aqueous layer was
extracted with EtO, and the combined organics were dried
(MgSO), filtered, and concentrated. Flash chromatography
(50% EtOAc/hexanes) gave 2 (6.75 g, 82%). On a larger

scale, 1 (50 g., 182 mmol) gave 2 in 72% yield (29.7g). H

CHO,: C, 58.83; H, 4.61. Found: C, 58.90; H, 4.71.
(5)

O
40

{ O OH
O

OH

45

meso-(1R*,2R*,3S*,4S*)-2,3-Bis(hydroxymethyl)1,4-epoxy-6.7-methylenedioxy-1.2.3,4tetrahy
dronaphthalene (5)

50

To a solution of the dimethyl ester 4 (25.0 g, 82 mmol) in
EtO (500 mL) at 0°C. was carefully added LiAlH4 (6.2g,
0.16 mol), and the resulting reaction mixture was refluxed for
1 day. Quenching was carried out by the sequential careful
addition of HO (6 mL: 30 min stirring), 15% NaOH (6 mL,
30 min stirring), and H2O (19 mL: 30 min stirring). The
mixture was neutralized with 1 NHCl solution (100 mL),
followed by the addition of HO (2.5 L) and extraction with
EtOAc (6.5 L). The organics were dried (NaSO) and con
centrated to give 5 as a white solid (16.8 g. 82%); mp 177

NMR. (200 MHz, CD) & 2.47 (t, J=6 Hz, 1H), 2.97 (s, 6H),
4.50 (d. J=6 Hz, 2H), 5.29 (s. 2H), 5.31 (s, 1H), 6.86 (s, 1H),

7.27 (s, 1H); 'CNMR. (125MHz, CD) & 52.8, 62.6, 101.6,

101.8, 108.4, 110.1, 130.4, 1348, 147.5, 148.4; HRMS (EI)
calculated for CHOs 226.0841, observed 226.0843. Anal.
Calculated for CHOs: C, 58.39; H, 6.24. Found: C, 58.20;
H, 6.07.

55

(3)
O

KOOO

COMe

COMe

60

1799 C.; H NMR (500 MHz, CD,OD) & 2.65-2.68 (ddd,
J=46.9 Hz, 2H), 2.77 (dd, J=9, 10 Hz, 2H), 3.15 (dd, J=6, 10
Hz, 2H), 5.24 (d. J=4 Hz, 2H), 5.90 (d. J=1 Hz, 1H), 5.94 (d.

Dimethyl 1,4-Dihydro-1,4-epoxy-6,7-methylene
dioxy-2,3-naphthalene-dicarboxylate (3)
65

The substrate 2 (23.7g, 105 mmol) was dissolved in excess
DMAD (251 g, 1.76 mol) and glacial AcOH (23.2 mL, 0.4

J=1 Hz, 1H), 6.85 (s, 2H); 'C NMR (125 MHz, CDN) &
44.6, 60.1, 82.4, 101.6, 103.6, 138.2, 146.7. Anal. Calculated

for CHOs: C, 62.39; H, 5.64. Found: C, 62.26; H, 5.59.
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20
(6)

(OOOC
O

meso-(1R*,2R*,3S*,4S*)-2,3-Bis(acetoxymethyl)-1,
4-epoxy-6.7-methylenedioxy-1,2,3,4-tetrahydronaph
thalene (6)

10

To a solution of 5 (57.g., 0.23 mol) and DMAP (1.4g, 11.4
mmol) in pyridine (750 mL) at -10° c. Was added AcO (69.9
g, 0.68 mol). The mixture was stirred for 16 hat room tem
perature and EtOAc was added. The organic phase was
washed with saturated NaHCO solution, 1 N HCl, and
CuSO (aqueous, Saturated). Drying (MgSO) and concen

15

2H); 'C NMR (75 MHz, CDC1) & 21.5, 40.6, 63.1, 82.2,

102.1, 103.8, 136.7, 147.6, 171.2: Anal. Calculated for

25

CHsO,: C, 61.07; H, 5.43. Found: C, 61.20; H, 5.61.
(7)
O

OH

(1S,2S,3R.4R)-2-Acetoxymethyl-1,4-epoxy-6,7methylenedioxy-3triisopropylsilyl-oxymethyl-1,2,3,
4-tetrahydronaphthalene (8)
To a solution of7 (14.5g, 49.6 mmol) and imidazole (7.4g,
0.11 mol) in DMF (150 mL) at 0°C. was added of TIPSCI
(11.7 mL, 54.6 mmol) and the mixture was stirred for 7 hat
room temperature. Et2O was added and the mixture was
washed with saturated aqueous NaHCO and water. The
organic phase was dried over MgSO filtered and concen

6.74 (s, 1H), 6.83 (s, 1H); 'C NMR (75 MHz, CDC1) & 12.5,
18.6, 21.5, 40.2, 44.3, 61.8, 63.3, 82.3, 82.9, 101.8, 103.6,
104.1, 136.9, 137.5, 147.1, 147.2, 171.3; C.D=+3.00 (c

0.9, CHCl); HRMS (FAB, 3-NBA, LiI) calculated for
CHOSiLi 455.2442, observed 455.2443.
30

(9)

OAc

35

(1R,2R.3S4S)-2-Acetoxymethyl-1,4-epoxy-3-hy
droxymethyl-6 7-methylenedioxy-1,2,3,4-tetrahy
dronaphthalene (7)
40

A5 LRB flask was charged with PPL (263 g, crude, Sigma)
and buffer solution (50 mM KPO, pH 7.8, 3.5 L). Diacetate
6 (20.0 g, 59.8 mmol) in DMSO (380 mL) was added via a
sidearm while stirring with a mechanical stirrer. The reaction
was quenched with 4 L of EtOAc after 2.5 hat room tempera
ture. Following centrifugation to remove insoluble material,
the organic layer was separated and washed with water. The
organics were dried over MgSO and concentrated. Flash
chromatography (50-80% EtOAc/hexane) gave in the follow
ing order 6 (4.1 g, 21%); 7 11.5 g. 66%; (83% based on
recovered 6), and diol 5 (0.7g, 5%). The monoacetate 7 was

determined to be 95% ee by examination of the "H NMR
spectrum of its derivative Mosher ester: mp 131-134° C.; H
NMR (360 MHz, CDC1) 81.43-1.58 (br. s. 1H), 2.06(s.3H),
2.77-2.84 (ddd, J–6, 9, 13 Hz, 2H), 2.87 (dd, J=9, 10 Hz, 1H),
3.23 (dd, J=10, 11 Hz, 1H), 3.28 (dd, J=6, 10 Hz, 1H), 3.76
(dd, J–6, 11 Hz, 1H), 5.25 (d. J=4 Hz, 1H), 5.32 (d. J–4 Hz,
1H), 5.94 (d. J=1 Hz, 1H), 5.98 (d, J-2 Hz, 1H), 6.75 (s, 1H),

45

50

OH

O

(1S,2S,3R.4R)-1,4-Epoxy-2-hydroxymethyl-6,7methylenedioxy-3triisopropylsilyl-oxymethyl-1,2,3,
4-tetrahydronaphthalene (9)
To a solution of acetate 8 (7.1 g, 15.8 mmol) in methanol
(60 mL) was added KCO (438 mg, 3.17 mmol). The result
ing Suspension was stirred for 1.5 h at room temperature,
DoweX 50x8 resin (H' form, 900 mg) was then added, and
stirring was continued for 30 min. The solution was filtered,
concentrated and the residue purified by flash chromatogra
phy (30% EtOAc in hexanes) to yield alcohol 9 (6.43 g,

100%). "H NMR (300 MHz, CDC1) & 0.98-1.07 (m, 21H),

J=5 Hz, 1H), 5.96 (s.2H), 6.73 (s, 1H), 6.76 (s, 1H); CNMR

55

(75 MHz, CDC1) & 12.4, 18.6, 44.4, 44.5, 61.1, 62.1, 82.0,

82.1, 101.9, 103.3, 103.4, 137.3, 137.6, 147.0, 147.1, IR

(ATR) 3419 cm-1; O'D=-26.8° (c 1.3, CHCl); HRMS

(FAB, 3-NBA, LiI) calculated for CHO Si Li 413.2336,

observed 413.2341.
60

(10)
O

61.0, 63.4, 82.3, 82.4, 102.0, 103.7, 103.8, 136.7, 137.2,

147.3, 147.4, 171.5; C.D=+52.6° (c 0.6, CHCl); HRMS
(FAB, 3-NBA) calculated for CHO 292.0947 M+),
observed 292.0952. Anal. Calculated for CHOs: C,

( O OTIPS

2.79-2.85 (m, 2H), 2.97-3.11 (m, 2H), 3.17 (dd, J=5, 11 Hz,
1H), 3.31 (dd, J–6, 10 Hz, 1H), 5.19 (d. J=4 Hz, 1H), 5.20 (d.

6.83 (s, 1H); 'C NMR (75 MHz, CDC1) & 21.5, 40.3, 43.8,

61.64; H, 5.52. Found: C, 61.72; H, 5.65.

OAc

CDC1) 01.03 (d. J=3 Hz, 18H), 1.03-1.22 (m, 3H), 2.06 (s,
3H), 2.76-2.77 (m, 3H), 3.14 (apt 1, J=10 Hz, 1H), 3.40-3.43
(m. 1H), 3.78 (dd, J=5, 11 Hz, 1H), 5.24 (d. J–4 Hz, 1H), 5.33
(d. J=3 Hz, 1H), 5.94 (d. J=1 Hz, 1H), 5.97 (d. J=1 Hz, 1H),

(300 MHz, CDC1) & 2.05 (s, 6H), 2.82-2.85 (m, 2H), 3.24
(dd, J=10, 11 Hz, 2H), 3.75 (dd, J–6, 11 Hz, 2H), 5.26 (d. J–4
Hz, 2H), 5.94 (d. J=1 Hz, 1H), 5.99 (d. J=1 Hz, 1H), 6.76 (s,

O

OTIPS

O

trated to give 7 as an oil (22.3g, 100%). H NMR (300 MHz,

tration provided 6 (7.6 g. 100%); mp 120-122° C.; H NMR

{

(8)

O

{

OAc

65

{ O OTIPS
O

CHO
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(1S,2R,3R.4R)-1,4-Epoxy-2-formyl-6,7-methylene
dioxy-3-triisopropylsilyloxy-methyl-1,2,3,4-tetrahy
dronaphthalene (10)

22

To a solution of oxalyl chloride (29 mL of a 2.0 M solution
in CHCl, 58.1 mmol) at -78°C. was added a solution of
DMSO (4.86 mL. 32.6 nmol) in CHCl (20 mL) via cannula.
After 10 min of stirring at -78°C., a solution of 9 (13.9 g, 34.2
mmol) in CH2Cl (20 mL) was added dropwise via cannula.
After an additional 30 minat -78°C., a solution of NEt (16.2
mL, 116 mmol) in CHCl (14 mL) was added. The resulting
reaction was allowed to warm to -40°C. and kept there for 2
h. EhO (500 mL) was then added at -40°C., and the reaction
mixture was allowed to warm to room temperature. The mix
ture was washed with H2O, aqueous NI LiCl, and brine. The
organics were dried (MgSO4), filtered, and concentrated to

5

10

15

1.20 (m, 21H), 2.99-3.12 (m, 2H), 3.22 (ddd, J=3.5.8 Hz, 1H),
3.46-3.51 (m. 1H), 5.38 (s, 1H), 5.40 (s, 1H), 5.96 (d. J=1 Hz,
1H), 5.98 (d. J=1 Hz, 1H), 6.84 (s, 1H), 6.85 (s, 1H), 9.07 (d.

J=3 Hz, 1H); 'CNMR (125MHz, CDC1) & 12.6, 18.6, 47.3,
54.2, 62.8, 81.0, 82.7, 102.0, 103.9, 104.0, 136.9, 137.5,

( CO OTIPS
O

give 10 (14.3g, 100%). "H NMR (300 MHz, CDC1) 80.97

25

147.4, 147.5, 202.5: O'D=-26.3° (c 0.8, CHCl); HRMS

COOH

(3R,4R)-6,7-Methylenedioxy-4-triethylsilyloxy-3triisopropylsilyloxymethyl-3,4-dihydronaphthalene
2-carboxylic acid (12)
To a solution of aldehyde 11 (900 mg, 2.25 mmol) in DMF
(20 mL) was added TESCI (715 JtL, 3.38 mmol) and imida
Zole (460 mg. 6.75 mmol) at 0°C. and the reaction mixture
was allowed to warm to r.t. overnight. Water was added and
the product was extracted with Et20, the organic layer dried
over MgSO and evaporated. The residue was then dissolved
int-BuOH (40 mL) and 2-methyl-2-butene (12 mL). A solu
tion of NaClO (1.81 g, 20 mmol) and NaH2PO (1.93 g) in
water (20 mL) was added and the mixture was stirred over
night. The product was extracted with EtO, dried over
MgSO4, concentrated and purified by silica gel column chro
matography (10-30% EtOAc in hexanes) to give the acid 12

as a white powder (1.02 g, 85% over 2 steps). H NMR (400

(FAB, 3-NBA, NaI) calculated for CHO, SiNa 427.1917,
observed 427.1925.
30

MHz, CDC1)00.65 (qJ=8.0Hz,6H), 0.94 (t, J=8.0 Hz, 9H),
1.06 (m, 21H), 3.05, (aptt, J=10 Hz, 1H), 3.34 (ddd, J=10.0,
4.5, 1.6 Hz, 1H), 3.77 (dd, J=10.0, 4.5 Hz, 1H), 5.03 (s, 1H),
6.03 (s. 2H), 6.81 (d. J=4.8 Hz, 2H), 7.67 (s, 1H).

(11)

H

{ CO OTIPS

(13)

QTES
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O

O

(12)

QTES

O

{ CO OTIPS

CHO

O

O
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(3R,4R)-2-Formyl-4-hydroxy-6,7-(methylenedioxy)3-triisopropylsilyloxymethyl-3,4-dihydronaphtha
lene (11)
To a solution of aldehyde 10 (10.5g, 26.0 mmol) in MeOH
(500 mL) was added NaOMe (1.40 g, 26 mmol) and the
mixture was heated to reflux for 5 h. HO (245 mL) was then
added, and CO was bubbled through the solution until the pH
reached 8 (pH paper). MeOH was removed in vacuo, and the
resulting aqueous layer was extracted with CH2Cl2. The com
bined organics were dried (MgSO), filtered, and evaporated

to provide 11 as a white solid (9.50g,90%): mp 87-89° C.; H
NMR (500 MHz, CDC1) & 0.93-103 (m, 21H), 1.74 (d. J=5
HZ, 1H), 3.17 (app t, J=10 Hz, 1H), 3.34 (ddd, J–2, 4, 6 Hz,
1H), 3.80 (dd, J=4, 10 Hz, 1H), 4.97 (app t, J=HZ, 1H), 6.01
(s, 1H), 6.02 (s, 1H), 6.83 (s, 1H), 6.93 (s, 1H), 7.24 (s, 1H),

9.61 (s, 1H); 'CNMR (125MHz, CDC1,) & 12.5, 18.5, 43.4,

cy
N

O
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(3R,4R)-6,7-Methylenedioxy-2-(N-oxazolidinonyl)
carbonyl-3-triisopropylsilyloxy-methyl-4-triethylsi
lyloxy-3,4-dihydronaphthalene (13)
50

55

60

62.7, 70.0, 102.4, 109.8, 110.9, 125.3, 133.8, 136.0, 145.6,

wise at -78° C. and the reaction mixture was allowed to stir

148.8, 150.7, 1929; IR (ATR) 3395, 1674, 1645 cm;
O'D+82.0° (c 1.0, CHCl); HRMS (FAB, 3-NBA) calcu
lated for CHO Si (M+H)" 405.2097, observed
405.2096. Anal. Calculated for CHO, Si: C, 65.31; H,
7.97. Found: C, 65.45; H, 7.98.

To a solution of acid 12 (94.0 mg, 1.76 mmol) in THF (20
mL) at room temperature was added carbonyl diimidazole
(428 mg, 2.64 mmol). The reaction mixture was stirred over
night, water was added and the product was extracted with
Et2O. The organic phase was dried over MgSO and evapo
rated to provide the crude acyl imidazolide, which was used in
the next step without further purification. To a deoxygenated
solution of 2-oxazolidinone (306 mg, 3.52 mmol) in THF (10
mL) at 78°C. was added n-Bulli (1.65 mL of a 1.6M solution
in hexanes, 2.64 mmol). After 1 h, a solution of acylimida
Zolide (1.06 g, 1.76 mmol) in THF (8 mL) was added drop

65

for 5 hat this temperature. The reaction was quenched with
water and extracted with EtO. The organic layer was dried
(MgSO), concentrated and the residue purified by column
chromatography on silica gel (hexanes/EtOAc/EtN, 90:10:

05 to 70:30:0.5) to yield 13 (650 mg, 62%). "H NMR (400

US 8,859,614 B2
24
was added and the product was extracted with EtO, the
organic phase dried over MgSO and evaporated. The product
was filtered through a short silica gel column (hexanes/
EtOAc 80:20) and used directly for the next step.
Typical Procedure for Desilylative Lactonization
To a solution of precursor 14-17 (0.21 mmol) in THF was
added TBAF (1.0 M solution in THF, 4 eq.). The mixture was

23
MHz, CDC1).J 0.65 (q, J=8.0Hz, 6H), 0.94 (t, J=8.0 Hz, 9H),
1.03 (m, 21H), 3.17, (aptt, J=10 Hz, 1H), 3.38 (ddd, J=10.0,
6.0, 1.6 Hz, 1H), 3.71 (dd, J=10.0, 6.0 Hz, 1H), 4.00 (m, 1H),
4.16 (apt qJ=9.0Hz, 1H), 4.49 (m, 2H), 4.99 (s.1H), 6.00 (s,

1H), 6.74 (s, 1H), 6.79 (s, 1H), 7.13 (s, 1H); 'C NMR (100

MHz, CDC1) & 5.0, 6.8, 11.9, 18.0, 44.1, 45.8, 61.8, 62.1,
68.5, 76.7, 77.1, 77.4, 1014, 109.2, 110.3, 125.0, 126.3,
131.4, 137.2, 147.5, 148.8, 153.5, 169.7.

refluxed for 30 minutes and allowed to cool to r.t. A saturated
10

(14)

QTES

solution of NHCl was added and the product was extracted
with EtO, the organic layer dried over MgSO and evapo
rated. The crude product was purified by silica gel column
chromatography (Hexanes/EtOAc, 7:3).

15

(18)

(15)

QTES
O

OTIPS
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N

OMe

O

4',5'-Didemethoxy-(-)-picropodophyllin (18)
30

From Michael acceptor 13 (0.23 mmol. 140 mg) 55 mg of

18 (68% over 2 steps) were obtained as a white powder. "H
OMe

(16)

OTE S

35

NMR (400 MHz, DMSO-d6) 02.50 (m, 1H), 3.38 (m hidden
under water peak, 1H), 3.76 (s.3H), 3.95 (d. J–7.2 Hz, 1H),
4.36 (dd, J=1004, 604 Hz, 1H), 4040 (dd, J=9.2, 604 Hz, 1H),
4049 (dd, J=9.2, 1.6 Hz, 1H), 5.92 (s. 2H), 5.94 (s, 1H), 5.97
(d. J=604 Hz, 1H), 6.84-6.89 (m, 3H), 7.07 (s, 1H), 7.32 (t,

J=8.2 Hz, 1H); C NMR (100 MHz, DMSO-d6) & 43.2,

40

4304, 44.3, 55.5, 67.7, 69.8, 101.2, 105.0, 107.7, 11204,
11504,121.8, 130. 1, 131.8, 135.3, 145.1, 146.2, 146.2, 159.9,

17804; HRMS (FAB, 3-NBA) calculated for C.H.O.
354.1103, observed 354.1100.
(19)

45

(17)

QTES
O

OTIPS

{

N

MeO

Cl

50

O
55

OMe
OMe

Typical Procedure for Introduction of E Rings (14-17)
To a suspension of CuCN (297 mg, 3.30 mmol) in THF (8
mL) at 5°C. was added 3.3 mL of a solution of the desired
mono ordi-methoxyphenylmagnesium bromide (1M in THF,
3.30 mmol). The resulting mixture was stirred for 30 min and
a solution of Michael acceptor 13 (250 mg, 0.41 mmol) in
THF (6 mL) was added dropwise at the same temperature.
After 1.5 h at 5°C., a saturated aqueous solution of NHCl

60

3',5'-Didemethoxy-(-)-picropodophyllin (19)
From Michael acceptor 13 (0.23 mmol. 139 mg) 50 mg of

19 (63% over 2 steps) were obtained as a white powder. "H
65

NMR (400 MHz, DMSO-d6) & 2.49 (app. q, J–7.0 Hz, 1H),
3.29 (dd, J=9.6, 7.8 Hz, 1H), 3.78 (s.3H), 3.92 (d. J=7.8 Hz,
1H), 4.36 (dd, J=10.0, 6.4 Hz, 1H), 4.39 (dd, J=9.2, 6.4 Hz,
1H), 4.49 (dd, J=9.2, 1.2 Hz, 1H), 5.91 (s. 2H), 5.92 (s, 1H),

US 8,859,614 B2
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5.95 (d. J=6.4 Hz, 1H), 6.96 (d. J=8.8 Hz, 1H), 7.06 (s, 1H),

26
7. EXAMPLE 2

7.19 (d. J=8.8 Hz, 1H); C NMR (100 MHz, DMSO-d6) &
In Vitro Testing of Inhibition of Cell Growth

42.6, 43.3, 44.6, 55.5, 67.7, 69.7, 101.2, 104.9, 107.7, 1144,
130.6, 132.4, 135.2, 135.4, 146.1, 146.1, 158.4, 178.5;

A murine breast cancer cell line derived from Kras mice

HRMS (FAB, 3-NBA) calculated for CHO 354.1103,
observed 354.1113.
(20)
10

15

was used to assay the effect of IGF1RK inhibitors. Approxi
mately 30,000 cells/well were plated in a 24-well plate which
corresponds to 20% confluence. The next day (Day 0 for the
experiment) two of wells were treated with MTT (Thiazol
Blue Tetrazolium), a substrate used in a colorimetric meta
bolic assay that reflects cell density. The cells in the rest of the
wells were treated with DMSO(PPP solvent), PPP or a deriva
tive of PPP at 500 nM concentration. Forty-eight hours later
the duplicate wells were assayed. The effectiveness of each of
the PPP derivatives was compared with that of the original
PPP

The five compounds listed in Table 1 were tested. The
results of the experiments with compounds 3 and 6 are shown
in Table 2.

OMe
OMe

TABLE 1

5'-Demethoxy-(-)-picropodophyllin (20)

25

Entry

Compound

1 (comparative)
2 (inventive)

(-)-picropodophyllin (PPP)
(-)-picropodophyllin analogue with 3'methoxy substitution on the E-ring (18)
(-)-picropodophyllin analogue with 4'methoxy substitution on the E-ring (19)
(-)-picropodophyllin analogue with 3,4'dimethoxy substitution on the E-ring (20)
(-)-picropodophyllin analogue with 3',5'dimethoxy substitution on the E-ring (21)

From Michael acceptor 13 (0.26 mmol. 160 mg) 40 mg of

3 (inventive)

NMR (400 MHz, DMSO-d6) & 2.49 (m, 1H), 3.37 (dd, J=9.6,
8.0 Hz, 1H), 3.73 (s.3H), 3.78 (s.3H), 3.89 (d. J=8.0 Hz, 1H),
4.35 (dd, J=10.0, 6.4 Hz, 1H), 4.40 (dd, J=8.8, 6.4 Hz, 1H),
4.50 (d. J=8.8 Hz, 1H), 5.91 (d. J–2.0 Hz, 2H), 5.96 (s, 1H),
5.97 (d. J=5.6 Hz, 1H), 6.79 (d. J=8.0 Hz, 1H), 6.87 (s, 1H),

4 (inventive)

20 (41% over 2 steps) were obtained as a white powder. "H

30

5 (inventive

6.96 (d. J=8.0 Hz, 1H), 7.06 (s, 1H); C NMR (100 MHz,

DMSO-d6) & 43.1, 43.4, 44.3, 55.9, 67.7, 69.7, 101.1, 104.9,

TABLE 2
35

Kras

107.7, 112.2, 113.0, 121.7, 132.4, 135.4, 135.5, 146.1, 146.1,

148.0, 149.2, 178.5; HRMS (FAB, 3-NBA) calculated for
CHsO384.1209, observed 384.1213.
40

Day 2

Day 2

Day 2

Day 2

cells

Day 0

18

21

PPP

No drug

1
2
Average

0.373
O.362
0.3675

O483
O.S66
O.S245

0.505
O.464
O4845

O.478
0.477
0.4775

O.959
O.625
O.792

(21)

45

O

Compound 18 appeared to be as effective as PPP at inhib
iting growth of the Kras breast cancer cell line. By varying
the concentration of compound 18, we obtained a preliminary
estimate of ~400 nM for ICs value, which very similar to the
behavior seen with PPP itself on this test cell line. Moreover,
the 4-methoxy compound (19) shows essentially no activity
under exactly the same conditions. Such a dramatic SAR
(Structure Activity Relationship) is quite remarkable.

50

MeO

8. EXAMPLE 3

OMe

In Vivo Testing
4'-Demethoxy-(-)-picropodophyllin (21)
From Michael acceptor 13 (0.25 mmol. 150 mg) 48 mg of

Mice

21 (50% over 2 steps) were obtained as a white powder. H
NMR (400 MHz, DMSO-d6) & 2.49 (m, 1H), 3.38 (dd, J=9.2,
8.0 Hz, 1H), 3.74 (s, 6H), 3.91 (d. J–7.2 Hz, 1H), 4.34 (dd.
J=9.60, 6.4 Hz, 1H), 4.40 (dd, J-9.0, 6.4 Hz, 1H), 4.50 (d.
J=9.0 Hz, 1H), 5.92 (s. 2H), 5.96 (d. J=6.0 Hz, 1H), 6.00 (s,

8.1. Materials and Methods

55

In addition to the mice conditionally expressing oncogenic
Kras (for details see EXAMPLE 5, Materials and Methods),
60

three mouse strains were used which have been described

previously; two cre-expressing strains, Hs-cre1 and Wap'
(Dietrich P. et al., Mamm. Genome (2000), 11:196-205; Lud
wig T, et al., Oncogene (2001), 20:3937-3948), and

1H), 6.45 (s.3H), 7.06 (s, 1H); C NMR (100 MHz, DMSO

Igflr' mice (Dietrich P. et al., Mamm. Genome (2000),

d6) & 43.1, 43.5, 44.1, 55.6, 67.7, 69.8, 98.8, 101.2, 105.0,
(FAB, 3NBA) calculated for CHsO 384.1209, observed

11:196-205). Molecular, histological, microarray and other
analyses were performed as described in EXAMPLE5. Mate

384.1221.

rials and Methods and Table 9.

107.7, 131.6, 135.3, 145.8, 146.2, 1610, 178.4; HRMS
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Drug Treatments
Details of the preclinical trial using picropodophyllin Syn
thesized as described (Buchardt O. et al. J. Pharm. Sci.
(1986), 75:1076-1080) and Erlotinib (purchased from Hwa
sun Biotechnology Co) are described in Results. The drugs
were dissolved in DMSO and cremophor (9:1) and injected
intraperitoneally. To calculate tumor volumes, the formula for
a prolate spheroid (L/6xaxb2 or -axb2/2, where a and b are
the major and minor axis, respectively) was used. The lengths
of axes were determined microscopically from sections of
tumor nodules using a computer assisted morphometry sys
tem (SpotAdvanced VS. 4.0.1, Nikon Eclipse E400). For
xenograft experiments, 5x106 MDA-MB-231 cells were
injected bilaterally into the fat pads of mammary glands 3 and
4 of female SCID/NOD mice. At ten days post injection,
when tumors were readily palpable, the mice were randomly
divided into two groups of five mice each and received the
same treatment (vehicle or PPP) described above for the
Kras mice for 3 weeks. For in vitro experiments, MDA-MB
231 cells were grown in DMEM supplemented with 10% fetal
bovine serum. Equal numbers of cells were seeded in multiple
wells of 24-well plates at low density (s.20% confluence at
day 0) and either DMSO or PPP dissolved in DMSO was
added to the medium (final concentrations: DMSO 01%, PPP
500 nM). Cell viability (duplicates) was measured on days 2,
4 and 6 by using the Thiazolyl Blue Tetrazolium Bromide
(MTT) colorimetric assay (Mosmann T.J. Immunol. Methods
(1983), 65:55-63).

5

28
Ubiquitous activation of Kras expression by removing the
floxed block using a cre transgene transcribed in 2-cell stage
embryos (Dietrich et al., Mammalian Genome (2000), 11:
196-205) caused embryonic lethality (not shown). On the
other hand, crosses of Kras' mice with partners expressing
Cre in particular tissues resulted in tumor development in the
pancreas, prostate, skin, intestine and the hematopoietic sys
tem.

10

15

25

8.2. Results and Discussion

Tumor Development in Mice Expressing Oncogenic Kras

A suitable mouse model has been identified to evaluate

Igflr as a potential therapeutic target in the context of our
research program aiming to generate mouse tumors by design

using a variant of a genetic scheme involving cre/loXP recom-

To activate expression of Kras in mammary glands, a
transgenic line (Ludwig et al. Oncogene (2001), 20, 3937
48) carrying cre inserted into the Wap locus, encoding a milk
protein, which is specifically transcribed in alveolar and duc
tal mammary epithelial cells during late pregnancy and
throughout lactation (Robinson et al., Development (1995),
121, 2079-90) was used. Unexpectedly, lactating females
with an Eef1a1-Kras/Wape genotype (n=28) developed
palpable multifocal, fully invasive tumors extremely rapidly.
Specifically, these malignant breast carcinomas appeared
within a period of 2 days to -2 months after the first delivery
of pups with a median time of tumor-free survival (Ts) of
only 9 days (FIG. 1D). This is believed to be the first descrip
tion of a mouse model in which a malignant neoplasm is
induced by a single tumorigenic stimulus in one step without
a requirement for secondary oncogenic events, as evidenced
by the rapidity of tumor development. This surprising obser
Vation of apparently single-step tumorigenesis can be attrib
uted to Kras overexpression at a very high level (23.5+5.8fold higher than that of endogenous Kras mRNA, n=4; see an
example of Northern analysis in FIG. 1C). However, Western

analysis indicated that the amount of total Kras (including the
mutant protein form) was only moderately elevated in the

neoplastic tissue in comparison with the wild-type (~4-fold:

FIG. 1C). Whether this is caused by poor translatability O

rapid turnover of the fusion Eefla 1/Kras transcript or some

bination (Politi K, et al. Oncogene (2004), 23:1558-1565).

other posttranscriptional mechanism remains unclear.

Depending on the tissue-specificity of the promoter driving

Histopathological Analysis of Kras-induced Mammary Car

Eefla1 is strongly transcribed (Soares et al., Proc. Natl. Acad.
Sci. U.S.A. (1994), 9,9228-32) and yields an abundant protein

of invasive carcinomas were identified at variable propor
tions: adenocarcinomas (Dunn Type A/B tumors), and pale,

cre expression, tumors develop at chosen anatomical sites of cinomas (see FIG. 2)
progeny derived by mating Cre-producers with mice carrying
a dormant oncogenic transgene that becomes functional after
Female mice developing tumors Were sacrificed when
excision of a floxed DNA segment blocking its expression. 40 moribund within a period of 9 days to -3 months (this brief
For development of a targeting cassette for high-level time of observation only rarely permitted the detection of
expression of any chosen cINA introduced into a defined lung metastases). In all examined cases (n=37), the Kras
genomic site by knock-in, the Eeflal locus (encoding a trans- induced carcinomas involved most or all mammary glands
lation elongation factor) was used as a recipient site for trans- and were either multifocal or consisted of large masses gen
genic knock-in of various sequences, including a constitu- 4s erated by coalescence of Smaller components. The tumors
tively active oncogenic Kras cDNA Kras 4B(G12D); Kras. were histologically heterogeneous and four coexistent types
product (-2% of the total cell protein: Codeelis, Trends Bio-

squamous and spindle cell (sarcomatous) carcinomas PCC,

chem.
Sri (1995),
20, 1B)
169-70).
the Eefla
targeting
SCC
and SRF,
sette (FIGS.
1A and
whichIn was
used here,
5' andcas.3
summarized
in EXAMPLEtheir
5, Table 3. of cancer forms are

regions of Eeflal gene homology are flanking a segment,
eventually targeted into the first intron of the locus, which
consists of a splice acceptor site, a floxed selectable marker
associated with a “stop” sequence and a cDNA, for example
Kras, inserted into chosen restriction sites of a polylinker.

Overall, however, the slow-growing adenocarcinomas,
which exhibited a very low proliferation index (-10-20% of
the corresponding value for any other component), were on
average the smallest tumor constituent (14% of the total
tumor mass; ~40-50% of the size of any other form; Table 3).

TABLE 3

Histopathological Analysis of Mammary Carcinomas
Adenocarcinoma (Dunn AB)

Pale Cell Carcinoma

Squamous Cell Carcinoma

Spindle Cell Carcinoma

37.2 + 4.7 (n = 37)
22.1 + 1.5 (n = 8)

24.7 + 4.5 (n = 37)
23.0 + 5.6 (n = 6)

A. Kras Tumors

Component size (%) 14.0 + 2.2 (n = 37)
Proliferation index

(%)

4.4 + 0.6 (n = 10)

24.7 + 5.1 (n = 37)
46.7 + 2.3 (n = 10)

US 8,859,614 B2
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TABLE 3-continued
Histopathological Analysis of Mammary Carcinomas

Spindle Cell Carcinoma
Solid nests of large pleomorphic Irregular nests of flattened
Fascicles of spindle-shaped
structures resembling budding cells with some (usually Small) eosinophilic cells of variable cells with elongated large
size
that
exhibit
distinct
cell
nuclei exhibiting infiltrative
alveoli and consisting of Small, degree of keratinization, which
possess lightly staining (pale') borders and clear evidence of growth (there are no defined
uniform-size cells with Small,
round, hyperchromatic nuclei
cytoplasm and nuclei. The pale keratinization (squamous
borders with the adjacent
(Dunn TypeA). Occasionally, cells are sometimes associated metaplasia). These nests are non-neoplastic tissue;
commonly
separated
by
broad
sarcomatous metaplasia).
Solid cords, nests or trabeculae with small basophilic cells with
bands of tumor stroma and
without glandular differentiation scant cytoplasm and ovoid
nuclei.
Surrounded by inflammatory
are detected (Dunn B).
Adenocarcinoma (Dunn AB)

Morphology

Squamous Cell Carcinoma

Pale Cell Carcinoma

Well-differentiated microacinar

infiltrate.

B. Kras' Tumors After Conditional Ablation of Igflr
Component size (%). 43.4+ 5.5 (n = 9)
Proliferation index

3.8 + 0.4 (n = 9)

15.9 + 6.9 (n = 9)
49.4 + 3.0 (n = 8)

19.4 + 8.3 (n = 9)
18.4 + 6.4 (n = 3)

21.4 + 6.6 (n = 9)
24.0 + 2.9 (n = 4)

(%)
It was observed that this form of carcinoma was histologically indistinguishable from a rare tumor type that appears specifically in the GR mouse strain carrying an active endogenous
MMTV provirus (Mtv2) on chromosome 18 (van Nie R and Dux A.J. Nati. Cancer inst. (1971), 46:885-897; Strum JM Am. J. Pathoi. (1981) 103: 283-291), but differed in
immunophenotype (not shown),

The Dunn adenocarcinomas were well-differentiated

microacinar structures (Dunn Type A) or occasionally solid
nests without glandular differentiation (Dunn Type B) and
corresponded morphologically to tumor types induced by the
mouse mammary tumor virus (MMTV; Hoeber-Harper, New
York), (1959) pp. 38–84; Sass B and Dunn TB, JNatl Cancer
Inst (1979); 62:1287-1293). On average, they were the small
est and slowest-growing tumor constituents (Table 3). The
PCC, which consisted of large, lightly-staining (“pale') cells,
were also adenocarcinomas, but exhibited in some areas signs
of keratinization. Morphologically, they are indistinguishable
from a rare tumor type that appears specifically in the GR
strain of mice carrying an active endogenous MMTV provi
rus (Mtv2) on chromosome 18. However, immunophenotypic

25

30

35

differences between the Kras- and MMTV-induced PCC

were identified. Clear evidence of keratinization (squamous
metaplasia) was seen in SCC, whereas the spindle-cell tumors
exhibited sarcomatous metaplasia. The microacinar (Dunn
A), pale and squamous cell tumors were correlated with the
presence of corresponding forms of carcinoma in situ (CIS:
also referred to in mice as “mammary intraepithelial neo
plasm', MIN; Cardiff R D et al., The Mouse in Biomedical

40

Research. Volume II. Diseases, Second ed., eds. Fox J Get al.,

(Elsevier, New York), (2007), pp. 581-622; FIG. 2A, insets).
Because the squamous CIS was rarely observed, we surmise
that it gives rise to invasive SCC very rapidly. A distinct
spindle-cell CIS was not found, but occasionally squamous
CIS exhibiting foci of sarcomatous metaplasia could be rec
ognized.
One type of carcinoma in situ (Small-cell, low nuclear
grade CIS) exhibited a pattern similar to that of lobular neo
plasia in human CIS. It was composed of Small cells filling

45

nated from the cytologically and immunophenotypically
identical invasive microacinar carcinoma Solely on the basis
of preservation of a myoepithelial layer. A second CIS type,
also retaining a discontinuous layer of myoepithelial (p63
positive) cells, formed multiple cellular layers in ducts, and
was also present in lobuloalveolar units, where it filled alveo
lar spaces in the form of Solid nests or nodules. This high
grade CIS was found either in isolation or adjacent to an
invasive component and consisted of large cells indistin
guishable in appearance and immunostaining characteristics
from those seen in PCC. Interestingly, in several independent
cases, conglomerates of large ductal CIS cells were observed
budding from a Suprabasal location outward to acquire a
position between the (still intact) luminal epithelial layer and
the overlying myoepithelial layer (at least in the human mam
mary epithelium, multilineage progenitor cells are thought to
reside in a suprabasal position). A third type of CIS was
composed of squamous cells and was the only one exhibiting
foci of sarcomatous metaplasia. Apparently, this CIS was
giving rise to invasive squamous cell carcinoma quite early, as
it was observed less frequently than the other forms.
To assess the origin, relationships and signaling character
istics of the carcinomas by immunophenotyping, an extensive
panel of markers was used (FIG. 2A, Table 4 and FIG. 6). The
results indicated that the ER"/PR" Dunn adenocarcinomas,
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which express exclusively luminal cell markers, such as
cytokeratin 18 (CK18; Krt18), are luminal-type cancers pre
sumably derived from differentiated luminal epithelial cells.
In contrast, on the basis of their distinct features, the pale,
squamous and sarcomatous carcinomas appear to correspond
to basal-like breast carcinomas.

lobules, but never extralobular ducts, and could be discrimi

TABLE 4

Immunophenotyping Data
Normal

CIS

V

P

L

I

PI

Ck18 (Krt18)

------

------

------

------

------

------

----

ER

ND

ND

IND

IND

ND

----

--

Carcinoma

Small Cell Large Cell Sq. Cell Dunn A/B PCC SCC SRC

Luminal markers
--

------

----

----

----

----
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TABLE 4-continued
Immunophenotyping Data

Normal

CIS

Carcinoma

V

P

L

I

PI

PR

ND

IND

IND

IND

IND

Small Cell Large Cell Sq. Cell Dunn A/B PCC SCC SRC
----

+f-

----

GATA3

------

------

------

------

------

------

----

------

-----------

-----------

-----------

-----------

-----------

----

Basal markers
Ck5 (KrtS)
Ck14 (Krt14)

+f----

-----------

-----

-----------

---------

+f-

+f-

--

------

--

------

+fND
ND
----

---ND
ND
------

+f------++

---------+++

------

--

------

--

----

------

+++

+++

+f-

---

------

SMA (Actg.2)

------

------

------

------

------

p63 (Trp63)

------

------

------

------

------

Itga.6
Itgb1
CD24
Ck6 (Krtó)

---ND
ND
----

+fIND
IND
+f-

+fIND
IND
+f-

+fIND
IND
+f-

-------------

Nestin

+f-

+f-

+f-

+f-

+f-

----

+f-

+f-

+f-

+f-

+f-

----

+f---

------------

-----

+f+f-

gflr

+f-

--

gf1

+f-

“Stem Cell markers

Annexin VIII
Sca1

ND
ND

-------

---+f-

+f-

Signaling markers
bErk
pAkt1
S6

--

+f-

----

----------------

--------------

----

----------------

--------------

----------

----

------

----

----

------

----

+f-

------

--

gf2
Egfr

Erbb2 (Neu)

----

--

--

--

----

--

------

------

--

---

--

--

+f-

--

--

--

--

--

--

----

--

--

------

------

--

---

------

------

--

-----------

---------

--

-----------

---------

-------

Erbb3

Notch 1
agged

----

++

Myc

---

------

----

--

--

--

--

--

------

------

------

------

Fos 1

+++

+++

+f-

------

----

------

- -

------

------

+f-

+++

+++

------

------

+f-

--

Other markers
E-cadherin

------

------

Vimentin

------

------

------

--

B-catenin (nuclear)
B-catenin (cell Surface)

------

----+++

+++

+++

+++

+++

------

------

------

------

---

------

The intensity of marker immunostaining signal (-: absent; +: weak in >15% of the cells; ++: focally strong; +++: generally strong) is compared between
wild-type mammary glands of virgin (V), pregnant(P), lactating (L), involuting (I) and postinvolutional (PI) female mice and in situ or invasive carcinomas,

The results indicated that the cancer forms induced by
Kras could be classified into two groups differing in the
cell-of-origin. Whereas expression of exclusively luminal
epithelial cell markers (such as keratin 18; Krt18) was
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detected in small-cell CIS and Dunn A/Badenocarcinomas,

the large-cell CIS and the pale, squamous and sarcomatous
carcinomas exhibited positive immunostaining both for lumi
nal markers (Krt18) and for basal cell markers (Krt5, Krt14.
p63), and also for presumptive stem cell markers. Apparently,
the Dunn adenocarcinomas, which are also hormone recep
tor-positive (ER"/PR), are luminal-type neoplasms, presum
ably derived from differentiated luminal epithelial cells,
whereas the ER/PR pale, squamous and sarcomatous
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tumors are basal-like cancers derived from undifferentiated,

bipotential precursor cells and not from myoepithelial cells,
as they do not co-express p63 and Smooth muscle actin
(SMA), which are the functional markers of myoepithelial
differentiation. This interpretation is also strongly supported
by expression profiling data.
On the other hand, a potential relationship between the
three basal forms is not a straightforward issue. For example,
it was considered that the PCC and the metaplastic and more
extensively keratinized squamous cell carcinomas (SCC),
which are often found intimately interspersed, might be
related and could represent two extreme forms of a spectrum
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of adenosquamous carcinomas. However, it may be more
likely that these two tumor forms originate from different cell
precursors, as suggested from the identification of distinct
CISS and the results of immunophenotyping. In regard to the
spindle-cell (sarcomatous) carcinomas (SRC), it is important
to note that they have lost the epithelial marker E-cadherin,
which is present in PCC and SCC, but strongly express
Vimentin, a mesenchymal cell marker. Nevertheless, as in
other cases of histopathologically heterogeneous mammary
tumors, the SRC presumably are epithelial and not mesen
chymal tumors that could be derived from an adenosquamous
component by EMT (epithelial-mesenchymal transition).
The term “precursor cell' is used herein to refer to the
cell-of-origin of the basal-like carcinomas that have been
identified in these experiments. It is notable that the PCC
expresses Gata3, a luminal cell marker for mature mammary
epithelium, which is absent from SCC. This difference may
by indicative of distinct cells of origin, but it cannot be inter
preted as suggesting that PCC could be derived from termi
nally differentiated luminal cells, as Gata3 is expressed in
precursor cells of mammary primordia. Differences in the
expression of particular markers, such as CK5/14 and p63,
also exist between SRC and the other two basal-like compo
nents (PCC and SCC). Nevertheless, the overall similarities
between the three basal forms, including the expression of
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putative stem cell markers and particular signaling compo
nents validated by molecular data, permit a clear-cut demar
cation from the luminal Dunn adenocarcinomas.
“Stem cell markers' should not be confused with “markers

of stemness', i.e. cellular constituents that bestow stem cell

behavior (self-renewal capacity and potential to generate dif
ferentiated derivatives) and/or are uniquely expressed in stem
cells. In fact, with the apparent exception of the Lgrš gene,
markers of sternness are generally unavailable. Instead, “stem
cell markers' correspond to an “expression signature' (i.e. a
combinatorial, rather than exclusive expression of some set of
cellular elements) capable of discriminating a cell population
enriched in operationally defined stem cells. Analysis of the
distribution of the CD29 (integrin B1; Itgb1) and CD49f(inte
grin C.6. Itga6) by using double immunofluorescence showed

10

15

that both of these markers were co-localized in the basement

membrane of the myoepithelial layer while, in addition, Itgb1
was present in the basolateral, but not the luminal aspect of
luminal cells. This distribution was maintained in microaci

nar adenocarcinomas, but only for Itgb1, whereas the basal
like forms had altered patterns. Thus, all SCC cells exhibited
intense labeling for both markers co-localized circumferen
tially, while the intensity of signal in PCC and SRC was
variable and did not involve all cells. An additional marker

that was examined was Scal, which was found to be present

25

in PCC and SCC, but not in SRC or Dunn tumors.

Of the three major molecularly classified subtypes of
human breast cancer (Perou C M. et al. Nature (2000), 406:
747-752: Sorlie T, et al. Proc Natl Acad Sci USA (2001),
98:10869-10874: Sorlie T, et al. Proc Natl Acad Sci USA

(2003), 100:8418-8423), luminal cancers are estrogen recep
tor-positive (ER), whereas the other two classes are ER
negative and either overexpress ERBB2 (ERBB2") or exhibit
phenotypic features of basal/myoepithelial cells (basal-like
cancers). The latter also lack progesterone receptor (PR) and
ERBB2 (“triple negative breast cancers'; see Da Silva L., et
al., J. Clin. Pathol. (2007), 60: 1328-1332: Reis-Filho J S and
Tutt AN. Histopathology (2008), 52:108-118), but frequently
express EGFR and basal markers, such as cytokeratins (CK)
5/6 and/or 14 and p63 (NielsenTO, et al., Clin. Cancer Res.
(2004), 10:5367-5374.). The basal-like group (15-20% of all
breast cancers), which is quite heterogeneous, includes high
proportions of BRCA1-associated and also medullary and
metaplastic (squamous, spindlecell and other) Subtypes.
Interestingly, KRAS amplification was detected in 56% (/16)
of examined basallike human breast cancers (HerschkowitzJ.
et al., Genome Biol. (2007), 8:R76).
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luminal markers chosen for classification of human breast
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On the basis of their distinct features, the Krasi-induced

ER/PR pale, squamous and sarcomatous mouse carcino
mas, which are immunopositive for both luminal (CK18) and
basal cell markers (CK5, CK14, p.63, and rarely smooth
muscle actin), and also for presumptive stem-cell markers
(Table 4), are analogous to some of the forms of human
basal-like cancers. It is likely that these basal-like murine
tumors are derived from undifferentiated, bipotential precur
sor cells and not from myoepithelial cells (this hypothesis
concerning "cells-of-origin' is discussed in detail in
EXAMPLE 5). Consistent with this view is the fact that the
Kras activating cre is embedded in the Wap locus that is not
expressed in fully differentiated myopithelial cells.
A morphological similarity between mouse pale cell car
cinoma and a type of human basal-like breast cancer that was
also correlated with KRAS copy gain, was observed. In a
collection of human breast cancer specimens (n=94), 17
samples (18%) were found to be basal-like (triple-negative
and positive for CK5/6), while 77 (82%) were non-basal (R.
Parsons and H. H., unpublished). Analysis of the 17 basal
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cancers for amplification of the KRAS locus by using CGH
showed that 5 of the specimens scored positive, while further
analysis of a subset by using FISH identified a sixth positive
sample. The corresponding KRAS amplification frequency in
the non-basal samples detected by CGH was 3/77 (-5% vs.
-35%, 6/17: P=0.002, Fisher's exact test). Three of the basal
like specimens with amplified KRAS displayed medullary
features (large tumor nodules with pushing, rather than infil
trative borders, composed of large cells with irregular, some
times bizarre nuclei growing in a syncytial fashion) but none
of them met all of the criteria for classical medullary carci
noma classification (they are referred to here as "atypical
medullary breast cancer, AMBC; Fadare O and Tavassoli F
A. Adv. Anat. Pathol. (2007), 14:358-373). Interestingly, two
of these AMBCs, contained abundant large cells with pale or
clear cytoplasm and exhibited a strong resemblance to the
histomorphological signature of the PCC observed in our
mouse model. To validate this correlation, an available set of
triple-negative AMBCs (n=8) was examined and it was
observed that most of them (7/s) were at least focally compa
rable to the PCC in Kras mice (FIG. 2B). Immuno-his
tochemical analysis showed that all 8 of these AMBCs were
positive for basal cytokeratins 5 and 14 and showed IGF1R
staining along their cellular surface (FIG. 2B). FISH analysis
was performed to assess potential amplification of the KRAS
locus and found that 3 of these cancers, all of which possessed
as a major component large pale cells, tested positive (FIG.
2C; P=0.015; using the data% for basal and 777 for non-basal
specimens). Therefore, the results showed that a subset of
basal-like human breast cancers preferentially exhibit ampli
fication of the KRASlocus frequently associated with a pale
cell carcinoma character.
Molecular Analysis of Kras-induced Mammary Carcinomas
To complement the morphological information described
above, the expression profiles of normal postinvolutional
mammary glands (n=5) and Kras-induced carcinomas
(n=14) were examined by microarray analysis, and it was
found that they were readily discriminated by unsupervised
hierarchical clustering (FIG. 7). Although the dendrogram
also stratified the tumors according to the predominating
basal-like component, only average differential expression
levels in tumors vs. normal glands was compared to simplify
the analysis (the microarray data were validated in part by
immunohistochemistry and Northern or Western blotting).
Comparisons of the profiling results with lists of basal and
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cancers (Sorlie et al., BMC Genomics (2006), 7:127; Hersch
kowitz et al., Genome Biol. (2007), 8, R76) and also with
datasets of upregulated and downregulated genes in basal and
non-basal breast cancers (Farmer et al., Oncogene (2005), 24.
4660-71; Richardson et al., Cancer Cell (2006), 9, 121-32)
showed unequivocally that the Kras-induced tumors are
basal-like carcinomas, in agreement with the histological evi
dence. In fact, the null hypothesis that there is no statistical
difference in the representation of basal and luminal markers
in the groups of upregulated and downregulated genes in
Kras tumors was overwhelmingly rejected (Table 5). In
addition, consistent with the hypothesis that the basal-like
Kras cancers evolve from precursor cells of the mammary
epithelium, the data showed that the pattern of overexpressed
genes in the tumors resembled much more the profile of a
mammary cell population enriched in stem cells than that of
another population consisting predominantly of luminal cells
(Stinglet al., Nature (2006), 439, 993-97; high statistical
significance: Table 5). Not unexpectedly, there was a high
degree of similarity between the profiles of Kras-induced
mouse lung (Sweet-Cordero et al., Nature Genet. (2005), 37.
48-55) and mammary tumors (Table 5). Finally, comparisons
of the microarray results with those for other mouse mam
mary tumors supported strongly the view that Kras deregu
lates to a much larger extent all major signaling pathways
(Tables 6-8).
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TABLE 5

Expression profiling data
Markers in the Profile of Krasi-induced Mammary
Cancers Represented in the Comparison Datasets

Upregulated (3154 total

Downregulated (2092 total

Markers in
Markers Common

Comparison Datasets (D)

Markers in
Common

(total #)

(#)

%

P

(#)

%

P

317
263
150
105

101
38
41
13

31.9
14.4
27.3
12.4

<1O-6

37
47
15
2O

11.7
17.9
1O.O
19.0

O.O1

1341
1520
1.191
858

453
327

<1O-5

362
229

33.8
21.5
30.4
26.7

154
263
131
140

11.5
17.3
11.O
16.3

D5a: “Stem Cell Markers

243

119

49.0

3 x 10

D5b: Luminal Markers

222

64

28.8

487
439

183
92

37.6
21.0

Human Breast Cancer

D1a: Basal Markers
D1b: Luminal Markers
D2a: Basal Markers
D2b: Luminal Markers

D3a: Upregulated in Basal-like Cancers
D3b: Downregulated in Basal-like Cancers
D4a: Upregulated in Basal-like Cancers
D4b: Downregulated in Basal-like Cancers

OOO2

OOO7

O.O2

2 x 10
10-4

Mouse Mammary Cells
35

14.4

47

21.2

S4
164

11.1
37.4

O.O15

Kras-Dependent Expression
D6a: Upregulated in Mouse Lung Cancer
D6b: Downregulated in Mouse Lung

<1O-6

<106

Cancer

Markers of the indicated datasets D1-D6 (filtered as described in EXAMPLE 5 Methods) are from Sorlie T, et al. BMC Genomics (2006) 7:
27; Herschkowitz J., et al. Genome Bioi (2007), 8: R76; Farmer Petal. Oncogene (2005), 24:4660-4671; Richardson AL, et al. Cancer Ceil
(2006), 9:121-132; Stingl J, et al. Nature (2006), 439:993-997; Sweet-Cordero A, et al. Nat Genet (2005), 37:48-55. For sets D3 and D4, we
used the meta-analysis data of the Oncomine database (www.oncomine.org),

TABLE 6

Expression of signaling pathway components in mouse mammary tumors
Kras
Pathway

Neu

Mye

# Total. A

#

%

# Total B

#

%

P

i

%

162
66

3S
19

21.6
28.8

140
62

14
9

10.0
14.5

O.OO3
O.O2S

8
4

5.7
6.5

mTOR

2O

1O

SO.O

19

2

10.5

O.OO8

6

Erbb
Wn

25
85

13
26

S2.0
30.6

2O
74

3
1

15.O
O.OO9
14 s-10

O
3

Notch

42

15

35.7

37

1

2.7

O.OOO2

3

8.1

23 37.7
22, 19.8

48
89

4
6

8.3
6.7

O.OOO2
O.OO45

2
2

4.2
2.2

19
10

O
1

O
100

O.OO)4
NS

1
O

5.3
O

32
4
3

Mapk
Pi3k

Tgfb
Jaki Stat

61
111

Hedgehog
Vegf

19
10

7
4

36.8
40.O

Cell Cycle

88

48

S4.5

82

19

23.2

2 x 10

Apoptosis
>1 Pathway

61
43

18
16

29.5
37.2

56
39

5
4

8.9
10.3

O.OO3S
O.OO3S

Tag
P

DMBA

i

%

P

i

%

P

4 x 10
7 x 10

13
3

9.3
4.8

O.O2
OOOO2

31.6

NS

1

5.3

O.OO2

O
4.1

7 x 10
6 x 10

1
7

S.O.
9.S.

O.OOO6
O.OOO6

O.OO3

2

S4

OOOO8

2 x 10
6 x 10

4
4

8.3
4.5

O.OOO3
O.OOO8

9.3
4.8
15.8
S.O.
10.8
S4
8.3

O.OO2
OOOO2
O.O2
O.OOO6
OOO1
O.OOO8
O.OOO3

2.2

6 x 10

O.O2
O.04

O
2

O
2O.O

O.004
NS

39.0

O.O2

41

SO.O

NS

7.1
7.7

O.OO1
O.OO1

4
5

7.1
12.8

O.OO1
OOO8

13
3
3
1
8
2
4
2
O
1
25
1
1

O.OO)4
1O.O
NS
3O.S.
O.OOO8

1.8
2.6

2 x 10
6 x 10

“Only upregulated genes are considered (see Table 9 for a list of genes encoding signaling components that are upregulated in carcinomas induced by Kras). The total number (ii) of unique

components in each major signaling pathway (listed in Table 8) is shown in columnA, except for the lastrow (components participating in more than one pathway), The number ofapathway
components that are overexpressed in Kras-induced cancers are compared with the corresponding numbers reported (Herschkowitz, J.I. etal. Genome Bioi (2007), 8: R76) for two luminal
type mammary tumors induced by Neu (Erbb2) or Myc, a basal-like cancer induced by DMBA administration and a tumor with mixed basal and mesenchymal characteristics induced by
Tag (SV40 large Tantigen). For the reported cases, the total number of components (columnB) is less than that in column A (the missing entries are not represented in the Affymetrix 430
2.0 chip that we have used). The percentages of overexpressed, pathwayspecific genes are higher in the Kras' than in the other tumors, Statistical analysis (Fisher's exact test) comparing
the expressed and nonexpressed components in Kras' tumors with the corresponding data of each of the other cases shows that there are highly significant differences (columnsP) with
very few exceptions (NS). Analogous differences were not observed for downregulated genes.

TABLE 7

Components of signaling pathways overexpressed in Kras'-induced carcinomas
SYMBOL

NAME

Arrb2

arrestin beta 2

Atf2
Atfa.
Braf
Dusp14

activating transcription factor 2
activating transcription factor 4
Braftransforming gene
dual specificity phosphatase 14

CN

Rac/MAPK Pathway
2.8

2.7
2
3.1
10.2

2.8

2.5

3.7
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TABLE 7-continued

Components of signaling pathways overexpressed in Kras'-induced carcinomas
SYMBOL

NAME

CN

Dusp15
Dusps
Dusp6
Dusp7
Dusp9

Dual specificity phosphatase 15
dual specificity phosphatase 5
dual specificity phosphatase 6
dual specificity phosphatase 7
dual specificity phosphatase 9

2.6
3.5
6
13.8
7.7

Flna
Flimb

filamin, alpha
filamin, beta

2.7
9.2

Gna12
Hras1

guanine nucleotide binding protein, alpha 12
Harvey rat Sarcoma virus oncogene 1

Map2k3
Map2k4
Map3k1
Map3k7
Map3k7ip2
Map4k4
Mapk13
Mapk14
Mapk9ip2
Mapk8ip3
Mapkapk2

mitogen activated protein kinase kinase 3
Mitogen activated protein kinase kinase 4
mitogen activated protein kinase kinase kinase 1
mitogen activated protein kinase kinase kinase 7
mitogen-activated protein kinase kinase kinase 7 interacting protein 2
mitogen-activated protein kinase kinase kinase kinase 4
mitogen activated protein kinase 13
mitogen activated protein kinase 14
mitogen-activated protein kinase 9 interacting protein 2
mitogen-activated protein kinase 8 interacting protein 3
MAP kinase-activated protein kinase 2

7
3
2.1
2.5
2
2.7
2.5
2.9
3.1
2.7
2.4
3.1
3

Nras

neuroblastomaras oncogene

3.7

Pak1
Pdgfa
Pdgfrb
Ppm1b
Ppp5c
Rasa1
Rras2

p21 (CDKN1A)-activated kinase 1
platelet derived growth factor, alpha
platelet derived growth factor receptor, beta polypeptide
Protein phosphatase 1B, magnesium dependent, beta isoform
protein phosphatase 5, catalytic Subunit
RAS p21 protein activator 1
related RAS viral (r-ras) oncogene homolog 2

3.3
2.5

2.5
2.2
3.3
3.1
2.5

Stmin1
Taok1

stathmin 1
TAOkinase 1

3.4
5.4

2.8

2

2.5

2.4

Phosphatidylinositol Pathway
Akt1

thymoma viral proto-oncogene 1

Akt3

thymoma viral proto-oncogene 3

19

Calm3
Calm4
Calml3

calmodulin 3
calmodulin 4
calmodulin-like 3

DgkZ
inpp11
itpr1
itpris
Ocrl
Pik3cg
Pik3r3
Pip5k1a.
Pip5klb
Pip5k2a
Plp5k2c
PC3
Syni 1
Synij2

diacylglycerol kinase Zeta
inositol polyphosphate phosphatase-like 1
inositol 14,5-triphosphate receptor 1
inositol 1,4,5-triphosphate receptor 3
oculocerebrorenal Saydrome of Lowe
phosphoinositide-3-kinase, catalytic, gamma polypeptide
phosphatidylinositol 3 kinase regulatory Subunit, polypeptide 3 (p55)
phosphatidylinositol-4-phosphate-5-kinase, type 1 alpha
Phosphatidylinositol-4-phosphate-5-kinase, type 1 beta
phosphatidylinositol-4-phosphate-5-kinase, type II alpha
phosphatidylinostiol-4-phosphate 5-kinase, type III, gamma
phospholipase C, delta 3
Synapiolanin 1
synapiolanin 2

2.5

2.2

2.5
2.9
34.2

2.3

2.4
4.2
2
6.7
2.5
2.2 S
2.3
2.9
2.4
2
2.1
5.8
3.3
2.4
3.2

mTOR Pathway
DditA
Eifa-E
Eifa-e2

Frap1
Hf1a
Rpséka1
Rpsékað
Rpsékb1
Rpsékb2
Uk1

DNA-damage-inducible transcript 4
eukaryotic traslation initiation factor 4E
eukaryotic translation initiation factor 4E member 2
FK5D5 binding protein 12-rapamycin associated protein 1
hypoxia inducible factor 1, alpha subunit
ribosomal protein B6 kinase polypeptide 1
ribosomal protein B6 kinase polypeptide 6
ribosomal protein B6 kinase, polypeptide 1
ribosomal protein B6 kinase, polypeptide 2
Unc-51 like kinase 1 (C. elegans)

10.2
2.9
2.7

2.4
2.4
2.1
7
2.8
2.2
2.3

3.5
6.4

Erbb Pathway
A reg
Ct
Ctlc
Ertb2

amphiregulin
Casitas B-lineage lymphoma
Casitas B-lineage lymphomac
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2

57.5
4.1
2.3
3.1

Ereg

epiregulin

Hbegf
Nick2

heparin-binding EGF-like growth factor
non-catalytic region of tyrosine kinase adaptor protein 2

33.S

Nrg1
Nrg3

neuregulin 1
neuregulin 3

3.9
4.9

Shc1
Shc4

Src homolog 2 domain-containing transforming protein C1
SHC (Src homology 2 domain containing) family, member 4

6.5
5.5

2.5

2.6
4.5

101S
3.7

2.3
4.2
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TABLE 7-continued

Components of signaling pathways overexpressed in Kras'-induced carcinomas
SYMBOL

NAME

Src.

Rous sarcoma oncogene

Tgfa

transforming growth factor alpha

CN

4.1

7.6

Wnt Pathway
Axin1

axin 1

CSnk2a1
CSnk2a1
CSnk2a1
CSnk2a2
CSnk2a2
Ctanb1
Ctanb1
Ctnnbip1
Daam1
Dkk2
Dw11
Dw11
FZ2
FZ2
FZd6
FZd6
Lrp5

casein kinase 2, alpha 1 polypeptide
casein kinase 2, alpha 1 polypeptide
casein kinase 2, alpha 1 polypeptide
casein kinase 2, alpha prime polypeptide
casein kinase 2, alpha prime polypeptide
catenin (cadherin associated protein), beta 1
catenin (cadherin associated protein), beta 1
catenin beta interacting protein 1
dishevelled associated activator of morphogenesis 1
dickkopfhomolog 2 (Xenopus laevis)
dishevelled, dsh homolog 1 (Drosophila)
dishevelled, dsh homolog 1 (Drosophila)
frizzled homolog 2 (Drosophila)
frizzled homolog 2 (Drosophila)
frizzled homolog 6 (Drosophila)
frizzled homolog 6 (Drosophila)
low density lipoprotein receptor-related protein 6

Nfats
Nfats

Nuclear factor of activated T-cells 5
nuclear factor of activated T-cells 5

Nkd1
Nkd2

naked cuticle 1 homolog (Drosophila)
Naked cuticle 2 homolog (Drosophila)
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR55), alpha isoforme
prickle like 1 (Drosophila)
prickle like 1 (Drosophila)
prickle like 1 (Drosophila)
prickle like 1 (Drosophila)
RuvB-like protein 1

Fpp2rla
Prickle1
Prickle1
Prickle1
Prickle1
Ruwbl1

Senp2
Sfrp1
Sfrp1
Sfrp1
Sfrp1
Tb1x
Tb1x
Tcf72
Vangl2
Wint10a
WintSa
Wnt7b
Wnt7b
WintSa

3.5

3.4
15.4
2.5
3
2.4
4.7
2.4
2.5
3.3
5.4
2
2
14.5
3.5
2.3
2.5
3.7

2.3

2.1
2.6
8.3

3.1
2.5

SUMO?sentrin specific peptidase 2
secreted frizzled-related sequence protein 1
secreted frizzled-related sequence protein 1
secreted frizzled-related sequence protein 1
secreted frizzled-related sequence protein 1
transducin (beta)-like 1 X-linked
Transducin (beta)-like 1 X-linked
Transcription factor 7-line 2, T-cell specific, HMG-box
vang-like 2 (wan gogh, Drosophila)
wingless-related MMTV integration site 10a
wingless-related MMTV integration site 5A
wingless-related MMTV integration site 7B
wingless-related MMTV integration site 7B
wingless-type MMTV integration site 5A

2.2
2.9
2.4
14.8
2.7
3.2
5.9
2

5.8
3.6
2.6

2.2
2.8 2.7
5.8 5.4
3
8.2
3.9 12.1
13.3
3
3.2
3.2
4.5
S.1
3.2
4.1
2.9

2.4
4
3.4
2.7
3.6
6.4

Notoh Pathway
Adam10
Adam17
Aph1a.
D14
Dtx3

a disintegrin and metallopeptidase domain 10
a disintegrin and metallopeptidase domain 17
anterior pharynx defective 1s homolog (C. elegans)
cells-like 4 (Drosophila)
cellex 3-like (Drosophila)

2.5
3.1
4
2
2.1
4.5

F1

four and a half domains 1

Gcins2

GCNS general control of amino acid synthesis-like 2 (yeast)

2.7

Hdse2
HeS1
Jag1
Jag2
Nicor?
Notch1
Notch3
Snw1

histone desacetylase 2
hairy and enhancer of split 1 (Drosophila)
jagged 1
jagged 2
nuclear receptor ca-repressor 2
Notch gene homolog 1 (Drosophila)
Notch gene homolog 1 (Drosophila)
SNW domain containing 1

4.3
2.7
7.6
2.3
3
2.3
6.1
4.5

Acwr1
Acwr1b
Acwr2a
Bmp7
Bmprlb
Bmpr2

activin A receptor, type 1
activin A receptor, type 1B
Activin receptor IIA
bone morphogenetic protein 7
bone morphogenetic protein receptor, type 1B
bone morphogenetic protein receptor, type II (serinethreonine kinase)

3.1
2.1
2.9
4
2.8
3.5

Tgrb Pathway

Fst

follistatin

4.1

Id1
Id4

inhibitor of DNA binding 1
inhibitor of DNA binding 4

2.5
5

Inhba

inhibin beta-A

Smad1

MAD homolog 1 (Drosophila)

2O2

3.4

S.1
2.3

2

3.6

2.5

2.1
5.7
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TABLE 7-continued

Components of signaling pathways overexpressed in Kras'-induced carcinomas
SYMBOL

NAME

Smad3
SmadS
Smadf
Smurf1
Smurf2
Sp1
Tgfb1
Tgfb2
Tgfbr1
Tgfbr2
ThbS1

MAD homolog 3 (Drosophila)
MAD homolog 5 (Drosophila)
MAD homolog7 (Drosophila)
SMAD specific E3 ubiquitin protein ligase 1
SMAD specific E3 ubiquitin protein ligase 2
trans-acting transcription factor 1
transforming growth factor, beta 1
transforming growth factor, beta 2
Transforming growth factor, beta receptor I
Transforming growth factor, beta receptor II
thrombospondin 1 i? similar to thrombospondin 1

CN

2.1
3.1
3.4
2.9
3.7
5.7
4.5
2.4
2.9
2.2
5

Thbs2

thrombospondin 2

3.5

6.3

S.1

2.4

3.7

Jak Stat Pathway
Ctcf.1
Cntf
CSf2
Csf3
Csf3r

cardiotrophin-like crystalline factor 1
cllary neurotrophic factor
calony stimulating factor 2 (granulocyte-macrophage)
calony stimulating factor 3 (granulocyte)
calony stimulating factor 3 receptor (granulocyte)

2.9
2.5
2.1
2.5
2.3

Ingr2
II13ra1

interleukin gamma receptor 2
interleukin 13 receptor, alpha 1

II2Orb
II23a

interleukin 20 receptor beta
interleukin 23, alpha subunit p15

3.4
2.8
4
3.3

2.6

14.1

12.7

2
2.7

13.5

II24

interleukin 24

II28ra
I4 ra

interleukin 28 receptor alpha
interleukin 4 receptor, alpha

3
2.3

I6
Jak3

interleukin 6
Janus kinase 3

2.2
2.1

Lif
Pias4
Socs3
SocSS

leukemia inhibtory factor
protein inhibtor of activated STAT 4
Suppressor of cytokine signaling 3
Suppressor of cytokine signaling 5

4.1
3.3
2.8
3.6

Spred1
Spred2

sprouty protein alth EVH-1 domain 1, related sequence
sprouty-related, EVH1 domain containing 2

3.5
4.6

Spred3
Stam2

sprouty-related, EVH1 domain containing 3
Signal transducing adaptor molecute (SH3 domain and ITAM motif)2

6.3
3.4

Cank1d

casein kinase 1, delta

2.8

Cank1g1
Cank1g2

casein kinase 1, gamma 1
casein kinase 1, gamma 2

5
2.1

Dhh
G3
PtCl2

desert hedgehog
GLI-Kruppel family member GLI3
patched homolog 2

4
2.2
2.5

Stk35

serinethreonine kinase 35 (fused homolog, Drosophila)

Pxn

paxlin

4.5

2.1

Sphk1
Vegfa
Vegfe

sphingosine kinase 1
vascular endothelial growth factor A
vascular endothelial growth factor C

4.8
2.5
3

2

2.1

Hedgehog Pathway

Vegf Pathway

2.5

2.2

2.5
2.4

2

2.2

Cell Cycle
Anapcs
Bub1
Bub1b
Bub3

anaphase-promoting complex subunit 5
budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae)
budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae)
budding uninhibited by benzimidazoles 3 homolog (S. cerevisiae)

2.2
10.3
5.4
2.3

Ccna2
Ccnb1
Ccnb2
Ccnd1
Ccnd2
Ccne2

cyclin A2
cyclin B1
cyclin B2
cyclin D1
cyclin D2
cyclin E2

7.6
17
11.5
10
3
3.3

Cdc20
Cdc23
Cdc25c
Colc2a
Cdc45
Cdc6
Cdc7
Cok4
Cdk6
Cdk7
Cokn1a
Cdkn1b
Cdkn2b

cell division cycle 20 homolog (S. cerevisiae)
CDC23 (cell division cycle 23, yeast, homolog)
cell division cycle 25 homolog C (S. pombe)
cell division cycle 2 homolog A (S. pombe)
cell division cycle 45 homolog (S. cerevisiae)-like
cell division cycle 6 homolog (S. cerevisiae)
cell division cycle 7 (S. cerevisiae)
cyclin-dependent kinase 4
cyclin-dependent kinase 6
cyclin-dependent kinase 7 (homolog of Xenopus MO15 colk-activating kinase)
cyclin-dependent kinase inhibtor 1A (P21)
cyclin-dependent kinase inhibtor 1B
cyclin-dependent kinase inhibtor 2B (p15, inhibits CDK4)

7.3
5.5
3
14.8
3.5
2.9
2.1
3.1
5.2
2.3
11.2
10.8
5.4

2

2.2
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TABLE 7-continued
Components of signaling pathways overexpressed in Kras-induced carcinomas
CN

SYMBOL

NAME

Chek1
Dbfa.
E2f1
E23

checkpoint kinase 1 homolog (S. pombe)
DBF4 homolog (S. cerevisiae)
E2F transcription factor 1
E2F transcription factor 3
extra spindle poles-like 1 (S. cerevisiae)
fizzyi cell division cycle 20 related 1 (Drosophila)

Espl1
Fzr1
Mad11
Mad21
Mcm2
Mcm3
Mcma.
Mcms
Mcmf
Mcm2
Orc1
Orc2l
Orc4
Plt1
Sfn

Skp2
Smc1a.
Wee1

Ywhag
Ywhah
YwhaZ

Apafl
Bad
Bax
Bcl21
BIrc4

Capn1
Casp3
Casp6
1a
11b

11 rap
rak2

Ngfb
Prkarla
Prkar2a
Tnfrsfl0b
Tradd

TrpS3

mitotic arrest deficient 1-like 1

MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast)
minichromosome maintenance deficient 2 mitotic (S. cerevisiae)
minichromosome maintenance deficient 3 (S. cerevisiae)
minichromosome maintenance deficient 4 homolog (S. cerevisiae)
minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae)
minichromosome maintenance deficient 7 (S. cerevisiae)
transformed mouse 373 cell double minute 2

origin recognition complex, Subunit 1-like (S. cerevisiae)
origin recognition complex, Subunit 2-like (S. cerevisiae)
origin recognition complex, Subunit 4-like (S. cerevisiae)
polo-like kinase 1 (Drosophila)
stratfin

S-phase kinase-associated protein 2 (p45)
structural maintenance of chromosomes 1A

wee 1 homolog (S. pombe)
3-monooxygenase tryptophan 5-monooxygenase activation protein, gamma
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, Zeta
Apoptosis
apoptotic peptidase activating factor 1
Bcl-associated death promoter
Bcl2-associated X protein
Bcl2-like 1

Baculoviral IAP repeat-containing 4
calpain 1
caspase 3
caspase 6
interleukin 1 alpha
interleukin 1 beta

interleukin 1 receptor accessory protein
interleukin-1 receptor-associated kinase 2
nerve growth factor, beta
protein kinase, cAMP dependent regulatory, type I, alpha
protein kinase, cAMP dependent regulatory, type II alpha
tumor necrosis factor receptor Superfamily, member 10b
TNFRSF1A-associated via death domain

transformation related protein S3

6.7
4.2
2.4
2.1
3.4
2.3
2.2
2.6
2.5
2.9
2.7
3.7
2.2
4.1
2.1
2.7
10
11
4.9
2.1
2.1
3.8
2.6
3.4

4.7
3.4
2.8
S.6
9.4
2.5
3.3
13
4.5
8.6

2.1

2.8
2
3.2

2.2
2

3.9
4.7
2.2
2
3.5

3.2
2.3
2.2
2.8
4.8

More than one Pathway
Crebbp
Cank1a1
Cankle

Ctbp2
Fbow11
Fos1
Gsk3b
Jun

Myc
Nfatc3
Nfatca.
NIk

Ppp2cb
Prkacb
Prkca

CRES binding protein
casein kinase 1, alpha 1
casein kinase 1, epsilon
C-terminal binding protein 2
F-box and WD-40 domain protein 11
fos-like antigen 1
glycogen synthase kinase 3beta
Junoncogene
myelocytomatosis oncogene
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4
Nemo like kinase

protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform
protein kinase, cAMP dependent, catalytic, beta
protein kinase C, alpha

5.5
S.1
10.1
2.3
3.6
9.2
6.2
4.8
2.4
3.4
2.4
4.3
2.3
3.6
2.4

2.5
2.2
4.6

2.1
2.3

C/N is the ratio or the level of expression in Kras tumors over normal mammary glands. The same ratio was calculated in tumors that eventually
developed after ablation of Igflr. The fold differences between the two ratios for genes that were upregulated () on downregulated () in the absence
of IGF signaling is indicated,
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Conditional Ablation of Igflr Delays Kras-induced Mam
mary Tumorigenesis
One of the most interesting changes detected in Kras
induced mammary cancers by RNA profiling was an
increased expression of Igflr, which was confirmed by Northern analysis. This prompted an investigation about the poten
tial involvement of IGF signaling in the development of mam
mary tumors in this mouse model.
A compelling reason for asking this question is evidence in
the prior art Suggesting that cells lacking Igflir cannot be
transformed by any one of several tested oncoproteins
(Baserga, Expert Opin. Ther. Targets (2005), 9, 753-68).
Apparently, Igflr-mediated signaling is not an oncogenic
component per se, but a crucial prerequisite for oncogenesis
considering that, among other effects, it provides a necessary
and strong antiapoptotic signal for tumor growth. The Igflr
gene is neither amplified nor obligatorily overexpressed in
human breast cancer. Thus, despite reported cases of overex
pression, it is not uncommon to detect Igflr mRNA levels that
are equal or even lower in cancer cells than in normal breast
tissue (Chong et al., Anticancer Res. (2006), 26(1A), 167-73).
Nevertheless, it is interesting that 36% of examined basal-like
breast cancers (n=64) were shown by immunohistochemistry
to be Igflr-positive (Lerma et al., Mod. Pathol. (2007), 20,
1200-07).
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cality and overall size of the carcinomas or in the proliferation
indices of the components were not noted (Table 3). On the
other hand, with the exception of SRC, significant alterations
were observed in the relative sizes of the components (Table
5 3). Interestingly, absence of only one Igflr allele (Eefla 1

Kras/Wap"/Igflr' animals) also resulted in a statistically

10

15

20

25

To examine the impact of the absence of Igflr on the
development of mammary tumors induced by Kras overex
pression, tumorigenic progression was compared between
animals carrying the oncogenic transgene in a background
either wild-type for Igflr (Eefla1-Kras/Wapcre mice serv- 30
ing as controls) or possessing one or two floxed Igflralleles
that could be conditionally ablated (Eeflal-Kras/Wapcre?

Igflr" and Eefla1-Kras/Wap/Igflr'? genotypes; n=11

and n=14, respectively).
It was observed that, in contrast to cancer manifestation 35

after the first birth with a T50 of 9 days in control mice,
ablation of both floxed Igflralleles in experimental animals
resulted in tumor development only after three pregnancies,
while the latency increased dramatically (11-fold; T50=101
days; P<0.0001, log-rank test; FIG. 1D). However, complete 40
rescue was not observed, perhaps owing to the occurrence of
mutational and/or epigenetic alterations compensating for the
absence of IGF signaling (Southern analysis confirmed that
Cre-mediated recombination had occurred in the Igflr locus,
while the tumors lacked Igflrexpression detectable by immu- 45
nohistochemistry or by Northern/Western analysis; data not
shown). Immunostaining for all examined markers (including
pAkt, pFrk1/2 and pS6) was virtually unaltered in the
Igflr-/- tumors, while significant differences in the multifo

significant delay in tumor appearance after a first pregnancy
(-5-fold increase in latency; P=0.01; FIG. 1D).
Comparison of the expression profiles of Kras cancers
developing in the presence or absence of Igflr signaling
revealed, among other effects (Table 9), significant differ
ences in transcript levels for Egfligands that were confirmed
by Northern analysis. Specifically, with intact Igflr, there was
>100-fold increase over normal in the amount of steady-state
mRNA for Hbegf present in the tumors, while the levels of
overexpressed transcripts for Areg, Ereg and Tgfa were less
dramatic (~4-, 15- and 6-fold, respectively). Interestingly, a
similar overexpression of Egf ligands was observed in an
HrasG12V breast cancer model (Sarkisian CJ, et al. Nat. Cell
Biol. (2007), 9:493-505), implying a more general feedback
loop involving Ras protein function. It was found that elimi
nation of Igflr only slightly affected the overexpression of
Areg, but resulted in the reduction of the Ereg and Tgfa
transcripts to almost normal levels, while the previously enor
mous amount of Hbegf mRNA was reduced approximately
by half. In contrast, Igfl and Igf2 transcripts encoding IGF
ligands were virtually absent from the tumors and Igfl and
Igf2 polypeptides were below detection limits by immuno
histochemistry (Table 4) indicating absence of IGF autocrine/
paracrine signaling cues. Accordingly, unless it is eventually
found that Igflr-mediated signaling is triggered by EGF
ligands acting through non-canonical IGF1R-EGFR het
erodimers (Riedemann, J., et al., Biochem. Biophys. Res.
Commun. (2007), 355, 707-714), it is likely that the IGF
functions are served in the Kras mammary cancers by endo
crine action of IGF1 circulating in serum. Assuming this to be
the case, it appears that IGF signaling potentiates Erbb-me
diated activities by upregulating Egf ligands through an
unknown mechanism, which could be transcriptional and
could involve Ap1 sites present in the promoter regions of
some of these ligands (Ornskov D, et al., Biochem. Biophys.
Res. Commun. (2007), 354:885-891). Interestingly, Fos11, an
Ap1 component, is highly overexpressed in the Kras' tumors
(FIG. 6 and Table 4). Three of the four Erbb receptors (Egfr,
Erbb2 and Erbb3) are present in the Kras tumors, but they
are not overexpressed. In fact, Erbb2 transcripts remain unde
tectable by Northern analysis, although the receptor itself can
be seen in the carcinomas by immunostaining (FIG. 6).
TABLE 9

List of primary antibodies
Antigen

Source

Name/Clone': Catalog No.

Retrieval

Incubation

CK18 (Krt18)
ER
PR
Gata
CK5 (Krt5)
CK14 (Krt14)
SMA (Actg2)
p63 (Trp63)
Itga.6
Itgb1
CD24
CK6 (Krtó)

Abcam, Cambridge, MA
Santa Cruz Biotechnology, Santa Cruz, CA
ABRAffinity Bioreagents, Golden, CO
Santa Cruz Biotechnology, Santa Cruz, CA
Cowance, Princeton, NJ
Covance, Princeton, NJ
Dako, Carpinberia, CA
BD Pharmingen, San Diego, CA
Santa Cruz Biotechnology, Santa Cruz, CA
Millipore Corp, Billerica, MA
BD Pharmingen, San Diego, CA
Cowance, Princeton, NJ

Clone C-04; ab668
H6.O
Polyclonal (Rb); sc-543
Ole
Clone PR-AT 4.14; MA1-410 pH6.0
Polyclonal(Gt); sc-1236
H6.O
Polyclonal (Rb); PRB-16OP
H6.O
Polyclonal (Rb); PRB-155P
H6.O
Clone 1A4; MO85129
H6.O
Clone 4A4: 559951
H6.O
Polyclonal(Gt); sc-6596
H6.O
Clone P4G11; MAB-1951
Ole
Clone M1/69; 557436
H6.O
Polyclonal (Rb); PRB-169P
H6.O

1 h RT, 1:200
1 h RT, 1:400
O/N 4° C., 1:50
O/N 4° C., 1:100
1 h RT, 1:500
1 h RT, 1:500
O/N 4° C., 1:200
O/N 4° C., 1:500
O/N 4° C., 1:50
O/N 4° C., 1:50
1 h RT, 1:200
1 h RT, 1:200

Nestin

DSHB, Iowa City, LA

Clone Rat 401c

H6.O

O/N 4° C., 1:50

Annexin VIII

Santa Cruz Biotechnology, Santa Cruz, CA

Polyclonal (Rb); sc-28825

H6.O

O/N 4° C., 1:200
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TABLE 9-continued
List of primary antibodies

Antigen

Source

Name/Clone': Catalog No.

Sca1
pErk
pAkt1
pS6
Igflr

Cedarlane Labs, Homby, ON
Cell Signalling Technology, Danvers, MA
Cell Signalling Technology, Danvers, MA
Cell Signalling Technology, Danvers, MA
Cell Signalling Technology, Danvers, MA

Clone CT-6A/6E: CL8934AP
Clone E10;9106
Polyclonal (Rb); 9277
Polyclonal (Rb): 2211
Polyclonal (Rb): 3027

Igf1

Dr. Louis E. Underwood

Igf2
Egfr
Erbb2 (Neu)

Upstate Biotechnology, Lake Placid, NY
Cell Signalling Technology, Danvers, MA
Santa Cruz Biotechnology, Santa Cruz, CA
Erbb3
BD PharMingen, San Diego, CA
Fos1
Santa Cruz Biotechnology, Santa Cruz, CA
Casp3(Asp175) Cell Signalling Technology, Danvers, MA
KI-67
Novus Biologicals, Littleton, CO
E-cadherin
BD Biosciences, San Jose, CA
B-catenin
BD Biosciences, San Jose, CA
Vimentin
Fitzgerald Industries, Concord, MA

Retrieval

Incubation
:50
:50
:50
:200
:200
:200
:50
:100
:200
:200
:100
:200
:100
:500
:100
:500

Clone S1 F2: 05-166
Polyclonal (Rb); 2232
Polyclonal (Rb); sc-284
Clone RTJ.1.554208

Polyclonal (Rb); sc-605
Polyclonal (Rb);9661
Clone SP6; NB110-57147
Clone 36: 610182
Clone 14: 610153
Polyclonal(Gp); PROGP53

Rb: rabbit; Gt: goat; Gp: guinea pig
pH6.0: antigen retrieval by boiling 15 minutes in 0.01M citrate buffer pH6.0
pH7.5: antigen retrieval by boiling 15 minutes in 0.01 MEDTA pH7.5

ON: overnight; RT: room temperature

Pharmacological Treatment of Kras-induced Mammary
Tumors

The strong genetic evidence for an Igflr role in mammary
tumorigenesis at least in the examined model is significant in
the context of efforts to develop therapeutic approaches for
treating breast cancer by blocking of IGF signaling. This
could turn out to be significant for basal-like carcinomas,
which have poor prognosis (Sorlie T, et al. Proc. Natl. Acad.
Sci. USA (2001), 98: 10869-10874) and pose a serious prob
lem to targeted therapies (Cleator S, et al., Lancet Oncol.
(2007). 8:235-244; Carey L. A. et al., Clin. Cancer Res.
(2007), 13:2329-2334), considering that the use of antiestro
gens in combination with trastuzumab (anti-ERBB2 anti
body) is not an option, while there is no clear choice for
chemotherapy. Therefore, the Kras model was used in a
preclinical study testing the efficacy of the cyclolignan
picropodophyllin (PPP), which has recently emerged as a
potent, nontoxic and highly specific Igflr inhibitor (Girnita,
et. al., Cancer Res. (2004), 64,236-42). Although the molecu
lar mechanism of PPP action is still unknown, its inhibitory
effects appear to be exerted by abrogation of Igflr phospho
rylation and promotion of its degradation, while the homolo
gous insulin receptor is not affected (Girnita, et. al., Cancer
Res. (2004), 64, 236–42; Vasilcanu, et al., Oncogene, (2008),
27: 1629-1638). Cell lines of Igflr null fibroblasts are appar
ently insensitive to PPP, whereas the drug reduces the viabil
ity of cancer cell lines and causes tumor regression in mouse
Xenografts of multiple myeloma (Menu et al., Int. J. Cancer
(2007), 121, 1857-61) and uveal melanoma (Girnita et al.,
Clin. Cancer Res. (2006), 12, 1383-91). Therefore, the Kras
model described herein was used for testing the potential
therapeutic effects of PPP on breast cancer. For this purpose,
PPP was administered either alone or in combination with

erlotinib, an Egfrinhibitor (Yang SX, et al., Clin. Cancer Res.
(2005), 11: 6226-6232), taking into consideration the over
expression of Erbbligands and Igflr/Egfr signaling relation
ships described above.
Miceata progressed stage of tumorigenesis bearing at least
one readily palpable tumor were injected intraperitoneally
once daily either with vehicle or with PPP and Erlotinib,
alone or in combination, at doses of 30 mg/kg and 50 mg/kg,
respectively, for a period of 3 weeks, considering that the
weight of Some tumors in the controls could reach or exceed

25

30

~1 g by that time. At the end of treatment, we measured tumor
growth relative to control values by calculating tumor mass,
and we did not attempt sequential measurements using a
caliper because a pilot study indicated that they were inaccu
rate. First, the tumors developing in each gland tended to be
multifocal and uneven, and progressively coalesced into
larger masses precluding reliable evaluation. In addition, the
treatment resulted in extensive tumor necrosis and fibrosis

35
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detectable only histologically, which would have artificially
inflated macroscopic measurements.
All glands carrying tumors in treated and control animals
were analyzed, and for statistical evaluation, it was taken into
account that the cancers exhibited pronounced size heteroge
neity (see FIGS. 3A-3F). On average, either Erlotinib or PPP
was effective and did not permit expansion of tumor Volume
per mammary gland beyond a level of -30% and ~7% of the
control value, respectively (Table 6). The effect of the drugs
used in combination (~4% of control) was perhaps only addi
tive (dose-response relationships were not yet studied).
Monitoring of body weights and histological examination of
various organs from vehicle- and drug-treated mice did not
reveal signs of non-specific toxicity.
TABLE 6

Drug treatments

50

Mice

Glands

Tumor volume

(n)

(n)

per gland (mm)

%

21
16
17
18

217.8 65.6
66.9 29.3
16.0 9.1
8.63.9

100
30.7
7.3
3.9

304 40.8
215 - 18.6

100
70.7

Pb

Mouse Tumors
55 Vehicle
Erlotinib
PPP
PPP - Erlotlib

Xenografts
60 Vehicle
PPP

5
5

O.O2

Mean S.E.M.

Because of data skewness, in tumor volume comparisons between the drug treatments and

the control (vehicle), probabilities (P) were calculated using Student's t-test after logarith
65

mic transformation of the values to meet the distribution criterion of the test.

Not unexpectedly, vehicle administration did not alter the
histopathological or immunophenotypic profile of tumors,
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whereas the specimens of mice treated either with PPP or with
a PPP/Erlotinib combination displayed a marked reduction or
even absence of the pale and squamous cell components
accompanied by extensive keratinization and vacuolation
(FIGS. 3A-3F). Thus, small cancerous lesions observed post
treatment consisted only of glandular and spindle cell types.
The extent of the latter, however, which exhibited degenera
tive changes, is difficult to quantitate. Erlotinib acting alone
reduced predominantly the pale cell component. However,
residual squamous cell carcinomas, whenever encountered
together with glandular and spindle cell components, exhib
ited extensive degenerative changes and marked tumor necro

52
ing in a syncytial fashion consistently lacking tubule forma
tion. However, none of these carcinomas metall of the criteria

for medullary carcinoma and, thus, they are referred to here as
"atypical medullary breast cancer (AMBC). Interestingly, 3/s
AMBCs with KRAS amplification, which in addition to their
syncytical/nodular growth pattern contained high numbers of
large cells with pale or clear cytoplasm, exhibited a strong
resemblance to the histomorphological signature of the pale
cell carcinoma observed in our mouse model. To confirm the
10

S1S.

To ascertain whether the reduction in tumor volume was a

consequence of decreased proliferation or increased cell
death, proliferation indices were determined, and as a mea
Sure of apoptosis, the expression of activated caspase-3 after
only 3 days of PPP or PPP plus Erlotinib treatment, i.e. prior
to a drastic decrease of the pale and squamous cell compo
nents was examined. It was observed that, while proliferation
was still at control levels, the numbers of caspase-3-positive
cells in the microacinar and non-glandular components were
2- and 9-fold higher, respectively, than in controls (FIG. 3C).
To evaluate IGF1R as a drug-target in human cells, the
receptor in MDA-MB-231 mammary cancer cells, which
possess a KrasG13D mutant gene (Kozma SC, et al., Nucleic
Acids Res. (1987), 15:5963-5971; Hollestelle A, et al., Mol
Cancer Res. (2007), 5:195-201) and share similarities in tran
scriptional profile with basal-like mammary tumor cell line
(Charafe-Jauffret E, et al., Oncogene (2006), 25:2273-2284)
was targeted. Pharmacological inhibition using PPP drasti
cally reduced the in vitro viability of MDA-MB-231 cells
(FIG. 8A). In addition, IGF1R knockdown using either a
dominant-negative form of the receptor or siRNA had an
analogous effect (FIGS. 8B and 8C). In a xenograft model in
NOD/SCID mice, it showed that tumor growth from orthoto
pically injected MDA-MB-231 cells was also attenuated in
PPP-treated mice in comparison with vehicle-treated controls
(Table 6). Although the in vivo effect of PPP on the highly
invasive MDA-MB-231 xenografts was overall less pro

15

noma character.
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8.3. Conclusion
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nounced than that observed with the mouse carcinomas, it

was statistically significant. In addition to other factors. Such
as poor vascularization making the drug less accessible, the
behavior of these xenografts derived from MDA-MB-231
cells that are more spindly than epithelial may be analogous to
the relatively reduced response of the SRC component of
mouse Kras tumors to PPP. Nevertheless, in conjunction
with the mouse data, these observations provide strong justi
fication for further evaluations of the drug against human
breast cancer.
KRAS and Human Breast Cancer

45

50

A comparison between the mouse mammary tumors
induced by K-rasactivation and human breast cancer is
shown in FIGS. 5A-5D. In a set of human breast cancer

specimens collected in the period between 1994 and 2003,
1794 (18%) were found to be basal-like (triple-negative),
while 77/64 (82%) were non-basal. Analysis of the 17 basal
cancers for KRAS amplification by using Southern blotting,
CGH and FISH showed that 5 of the specimens (-29%)
scored positive in at least two of these three assays (FIGS.
5E-5G show an example of the FISH results), whereas ampli
fication of the locus (detected by CGH) was found in only 4 of
the 77 non-basal samples (-5%; P=0.008, Fisher's exact test).
All 5 basal-like specimens with amplified KRAS displayed
medullary features, as they formed large tumor nodules with
pushing, rather than infiltrative borders and were composed
of large cells with irregular, sometimes bizarre nuclei grow

validity of this correlation, all of the available triple-negative
ABMCs (n=9) collected between 2005 and 2007 were exam
ined, and it was observed that most of them (%) were at least
focally comparable to the PCC in Kras mice. Immunohis
tochemical analysis showed that all 9 of these ABMCs were
positive for basal cytokeratins 5 and 14 and showed IGF1R
staining along their cellular Surface. FISH analysis was then
performed to assess potential amplification of the KRAS
locus and found that 3 of these cancers, all of which possessed
as a major component large pale cells, tested positive
(P=0.02; using the data 3/9 for basal and /77 for non-basal
specimens). These data indicate that a Subset of basal-like
human breast cancers exhibit preferentially amplification of
the KRAS locus frequently associated with a pale cell carci
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It has been shown that overexpression of oncogenic Kras
in mouse mammary glands leads to rapid development of
histopathologically heterogeneous malignant tumors pre
dominantly simulating human basal-like breast cancers, but
also including a luminal type. Although the incidence of
KRAS mutations in human breast cancer is not very high, it is
still appreciable (~7% in tumors and ~13% in cancer cell
lines; see Hollestelle A, et al., Mol. Cancer. Res. (2007),
5:195-201; Malaney Sand Daly R.J.J. Mammary Gland Biol.
Neoplasia (2001), 6:101-113). Moreover, in-70% of primary
breast cancers, the level of RAS is higher than that in normal
tissue (Dati C, et al. Int. J. Cancer (1991). 47:833-838). Such
elevated RAS activity is apparently required even for mam
mary carcinogenesis induced by RAS mutations (Sarkisian C
J, et al. Nat. Cell Biol. (2007), 9:493-505). Clearly, regardless
of cause (mutation and/or overexpression), the important ele
ment contributing to oncogenesis is the perturbation of the
Ras pathway, which can be dissected genetically by mouse
modeling. The diversity of cancerous forms and especially
the rapidity of tumor manifestation increases further the util
ity of the mouse model that have been described here, which
can be used advantageously after appropriate genetic testing
for preclinical evaluation of treatment regimes, as exempli
fied by our results.
Seemingly, the single-step tumorigenesis that has been
observed does not conform to the widely accepted multi-hit
model of carcinogenesis (Vogelstein B and Kinzler K W.
Trends Genet. (1993), 9:138-141; Hanahan D and Weinberg
R.A, Cell (2000), 100:57-70). However, from the standpoint
that cancer is a disease of malfunctioning cell signaling, all
cases of tumor development can be viewed, regardless of
timing, as variants of a more general hypothesis positing that
contributing “hits’ correspond to recruitment and combina
torial engagement of deregulated pathways predominantly
involved in apoptosis and growth control. Apparently, in the
case of our model, highly overexpressed, constitutively active
Kras can elicit synergism of downstream pathways that are
simultaneously deregulated to a degree Sufficient for rapid
development of invasive cancer. Analogous inverse reciproc
ity between Kras expression levels and tumor latency in
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development every day upon parturition and examined with
palpation for tumor development. Once tumors are readily
palpable (1-2 mm diameter), the tumor size and body weight

other mouse models has been observed other than the

extremely rapid development of carcinomas of the skin and
the oral mucosa induced by Kras observed by others (Vitale
Cross L., etal, Cancer Res. (2004), 64:8804-8807). It remains
to be seen whether, by exceeding normally affordable limits,
oncogene overexpression overrides homeostatic capabilities
and/or if the excessive deregulation that it causes permits
novel and abnormal signaling interactions.
An additional open question is why the constitutively act
ing oncogenic Kras, which has ceased to respond to
upstream effectors in signaling relays and has presumably
acquired autonomy in deregulating signaling, is not refrac
tory to the silencing of Igflr. Ras proteins control prolifera
tion through the Raf->MEK->Erk pathway, but also interact
directly with the p110 catalytic subunit of the PI3K complex,
thus affecting anti-apoptosis. It is notable, in this regard, that
loss-of-function missense mutations in the Ras binding
domain of p110 inhibit almost completely Kras and Hras
oncogenicity in mouse models of lung and skin tumors,
respectively (Gupta S, et al. Cell (2007), 129:957-968). The
mechanistic details in this case (involving a different tissue)
are unclear. However, a testable hypothesis is that, without the
crucial participation of Igflr signaling that exerts both PI3K
dependent and PI3K-independent anti-apoptotic effects, the
direct activation of the PI3K pathway by Kras is, despite its
overexpression, inadequate for attaining a level of anti-apo
ptosis able of promoting oncogenicity. It is noted that the
results of a previous study (Cristofanelli et al. Oncogene
(2000), 19:3245-3255) showing that 32D cells could become
tumorigenic by the combined action of Hras and Irs1 (a downstream effector of Igflr), but not by either one of these com
ponents acting alone, could also be interpreted as indicating a
collaboration between the Erk and PI3K pathways. Perhaps,
among other effects, Kras triggers in this case the operation
of a positive feedback loop that enhances its action through
the upregulation of Igflr expression which, in turn, could
amplify proliferative and anti-apoptotic signaling by increas
ing the expression of Egfligands. The downregulation of such
ligands by genetic inactivation of Igflr could explain why

of the mice are documented. Mice are then treated with either

5 vehicle or an IGF1RK inhibitor. Typically, mice are injected
daily with 100-150 ul of a solution containing 90% DMSO
and 10% of an emulsifier (Cremophor EL, Sigma). In this
solution, for example, PPP is completely soluble at a concen
tration of 6 mg/ml.
10 After 21 days of treatment, the mice are sacrificed,
weighed, and the initial tumors measured individually. In
addition, tumors which were not palpable at the time of initial
palpation, but had grown during the therapy period, are also
isolated. In an experiment comparing vehicle treatment with
15 PPP, the total tumor volume per mouse in the vehicle group

was 653+219 mm (number of mice: 7, total mammary gland

affected: 21). Mice treated with PPP showed a much slower
tumor growth with a total tumor volume per mouse of 54+28

mm (p=0.05) at the end of the study.
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10. EXAMPLE 5

10.1. Materials and Methods
Mice

Knock-in transgenic mice conditionally expressing onco
genic Kras were generated by standard procedures using tar
geted W9.5 ES cells. The targeting vector was prepared using
the Eefla 1 cassette described in FIG.1. The starting DNA to
provide homology arms (5'812 bp: 3' 3,606 bp) was a 4.418
30 bp SacII/Nhel fragment containing the entire Eefla 1 locus
except for the non-coding exon1. This fragment, isolated
from a genomic library of mouse strain 129/Sv in phage w
(WFIX II vector; Stratagene), was modified by introducing
into a unique Spel site proximal to the end of intron 1 a
35 PacI/PmeI/AscI linker to facilitate cloning. A mouse Kras
cDNA (referred to here as Kras) containing a G-> A nucle
otide substitution in codon 12 (GGT->GAT) was excised
from a plasmid (pBS.K.S.G12D.Ras4B.p.A. kindly provided
by Drs. D. Tuveson and T. Jacks, Massachusetts Institute of
PPP is more effective than Erlotinib in the treatment of Kras - 40 Technology, Cambridge, Mass.) and Subcloned into the
induced tumors. Presumably, pharmacological inhibition of pBigT vector (Srinivas S, et al., BMC Dev. Biol. (2001), 1:4).
Egfr alone does not attenuate tumor growth sufficiently A segment from this intermediate construct containing a
because the Egfligands are still expressed at high levels and splice acceptor site, a floxed Pgk-neo-triple poly(A) and the
can function through other receptors of the family (the most Kras cDNA was excised as a PacI/AscI fragment and cloned
likely candidates are Erbb2: Erbb3 heterodimers). In contrast, 45 into the corresponding sites of the PacI/PmeI/AscI linker
in addition to the direct pharmacological inhibition of Igflr described above.
activity by PPP, there is an indirect effect on Egf ligand Molecular Analysis
Standard protocols were followed for Southern, Northern
downregulation preventing the robust formation of homo or
and Western analyses. The probes used were a 616 bp Xbal/
heterodimers between the Erbb receptor family members.
50 SacII fragment immediately upstream from the 5' arm (South
9. EXAMPLE 4
ern) and the Kras cDNA described above (Northern). The
anti-Kras-specific antibody used for Western analysis was
In Vivo Testing
sc-521 (Santa Cruz, Biotechnology). To examine the effects of
dominant-negative IGF1R, plasmid 486Stop (D’Ambrosio
Mice were generated that carried the Ef1/Kras oncogenic 55 C, et al., Cancer Res. (1996), 56:4013-4020; kindly provided
mutation together with one or two alleles of the IGF1R locus by Dr. R. Baserga, Thomas Jefferson University, Philadel
conditionally knocked out (Xuan et al., J. Clin. Invest. 2002, phia) or control pcDNA3 plasmid were introduced into
110, 1011-19) and the WAPcre transgene (which would acti MDA-MB-231 cells grown in DMEM supplemented with
vate the oncogene and ablate the IGF1R gene in the same cells
10% fetal bovine serum by using a nucleofector (Amaxa
during pregnancy/lactation). Parous mice were observed for 60 Biosystems). RNA interference experiments with MDA-MB
the development of invasive tumors and compared the tumor 231 cells were performed as described (Rochester Mass., et
latency with control females that carried only the oncogene al., Cancer Gene Ther. (2005), 12:90-100) using the siRNA
and the WAPcre gene. In such mice, IGF1 Rinactivation has a duplex R4 sense strand 5'CAAUGAGUACAACUAC
profound effect on tumor latency, even in mice where only CGCTT3' (SEQ ID NO: 1); antisense strand 5'GCGGUAG
one of the two alleles is ablated.
65 UUGUACUCAUUGTT3' (SEQ ID NO: 2), which targets
To test the effect of IGF1RK inhibitors on tumor growth, the human IGF1R mRNA at nucleotides 639-657, and a
parous Efl/Kras: WAPcre mice are monitored for tumor scrambled control duplex Scra; sense strand 5' GUCACAC
25

US 8,859,614 B2
56
between groups were examined using Student's t test. The
null hypothesis that there is no marker difference in pairwise
comparisons between microarray datasets was evaluated
using Fisher's exact test.

55
CGAUAAGUCACATT3' (SEQ ID NO:3); antisense strand
5*UGUGACUUAUCGGUGUGACTT3' (SEQID NO:4).
Histological Analysis, Immunophenotyping, Flow Cytom
etry and FISH

10.2. Results and Discussion

Mouse tissues were fixed in 10% formalin, embedded in

paraffin, sectioned, and stained with hematoxylin and eosin.
The primary antibodies and the conditions used for immuno
histochemistry are listed in Table 9. Semiquantitative scoring
(- to +++) was according to the system used for HercepTestTM
(Dako), with - representing no staining, + weak staining
in >15% of the cells, ++ strong focal staining in <15-20% of
the cells, and +++ strong staining in >15-20% of the cells.
Immunofluorescence was performed on paraffin sections by
standard procedures. For flow cytometry, single cell Suspen
sions from mammary glands and tumors prepared as
described (Stingl J, et al. Nature (2006), 439:993-997) were
processed using the EasySep kit (StemCell Technologies)
and analyzed on a FACS Aria instrument (Becton Dickinson).
For fluorescence in situ hybridization analysis we used three
BAC clones (Invitrogen; RP11-157L06, RP11-583L24 and
RP11-707G18) spanning the human chromosome 12p12.1
region containing the KRASlocus. BAC DNA was labeled by
nick-translation using spectrum redd UTP fluorochrome (Ab
bott Molecular). A Spectrum green-labeled centromeric 12
(CEP 12) probe (Abbott Molecular) was used to enumerate
chromosome 12. FISH was performed by standard methods
and hybridization signals were scored on at least 100 inter
phase nuclei on DAPI-stained slides. The human breast can
cer specimens analyzed histologically or by FISH were
obtained from Surgical Pathology files of the College of Phy
sicians, Columbia University, following approval of the Insti
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CD24"/CD29' or CD24"/CD49f' cells (depleted of hemato

15

poietic contaminants; Lin), which were enriched in mam
mary gland-forming stem cells defined operationally by
cleared fat pad transplantation assays (Shackleton M, et al.,
Nature (2006), 439:84-88; Stingl J, et al., Nature (2006), 439:
993-997), exhibit phenotypic similarities with basal-like
tumors (Asselin-Labat M L, et al., J. Natl. Cancer Inst.
(2006), 98:1011-1014). Interestingly, comparative FACS
analysis of cell Suspensions isolated from Kras-induced
tumors (n-3) and normal mammary glands of age-matched
parous females (n=5) showed an increase in the number of

CD24"/CD49f" neoplastic cells (FIG. 9); the distribution of

25

the markers CD49f (Itgao; integrin C.6) and CD29 (Itgb1;
integrin B1) in Kras tumors is shown in FIG. 10). An addi
tional interesting marker present in PCC and SCC, but not in
SRC or Dunn tumors, was Scal (FIG. 6 and Table 4).

Although CD24"/CD49f" cells express high levels of Scal

30

tutional Review Board.

Microarray Analysis
For expression profiling, total RNA was extracted from
mammary tumors of Kras/WAP-cre bitransgenic or age
matched postinvolutional female mice. The samples were
profiled individually. For each assay, 5-8 ug of total RNA
were used to generate biotinylated cRNA that was frag
mented (15 ug) and then hybridized to Mouse Genome 430
2.0 Array DNA Chips (Affymetrix). The microarrays were
scanned (Affymetrix Scanner) and expression values for the
genes were determined using Affymetrix GeneChip Operat
ing Software 1.2. Filtering and further analysis using the raw
data was performed with GeneSpring 6.0 software. A ratio of
22 (experimental/control for “upregulated and control/ex
perimental for “downregulated entries) was used as a widely
accepted cut-off point indicative of a significant difference in
transcript levels. An unsupervised clustering dendrogram was
generated by using Cygwin Software. Literature data com
pared with our results (see Table 5) were filtered to select and
use only markers represented in the Affymetrix 430 2.0 chip,
which also corresponded to known genes (unknown EST's
were ignored) and were at least 2-fold upregulated or down
regulated in comparison with corresponding controls. For
comparative identification of signaling molecules (see Tables
6 and Table 7), key-members of all major signaling pathways
were listed in Table 8) and they were selected in a non
redundant fashion from the following databases: KEGG
(www.genome.ad.jp/kegg/kegg2.html), BioCarta (c.gap.nci.nih.gov/Pathways/BioCarta Pathways), Cancer Cell Map
(cancer.cellmap.org/cellmap), Pathway-Express (Vortex.cS.wayne.edu/ontoexpress) and Wikipathways (www.
wikipathways.org).
Statistical Analysis
Values were expressed as meantS.E.M. Results were con
sidered as statistically significant if P-0.05. For analysis of
Survival curves, a log-rank test was used. Differences

Example3 has shown that the Kras-induced murine mam
mary carcinomas are histopathologically heterogeneous and
include, in addition to three basal-like components, a luminal
type. On the basis of morphological and molecular criteria, an
advanced hypothesis is that the cells-of-origin of the basal
like carcinomas are epithelial progenitors. This is consistent
with observations indicating that populations of flow-sorted
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only after culturing (Vaillant F, et al., Stem Cell Rev. (2007),
3:114-123), this marker still belongs to a stem cell signature,
considering that cultured mammary epithelial cells with this
phenotype are able to repopulate cleared fat pads (Welm B E.
et al., Dev. Biol. (2002), 245:42-56). Nevertheless, the obser
vations are not sufficient to identify exact cell types and their
hierarchical standing in the cell lineage of the presumptive
precursors, despite Some clues. For example, Gata3, a marker
of mature luminal epithelium also expressed in precursor
cells of mammary primordia (Asselin-Labat ML, et al. Nat.
Cell Biol. (2007), 9:201-209), is present in PCC but not in
SCC (FIG. 6 and Table 4). This difference may be indicative
of distinct cells-of-origin, also Suggested by the identification
of distinct CISs. Differences in the expression of particular
markers, such as CK5/14 and p63, also exist between SRC
and the other two basal-like components (PCC and SCC). It is
noted that the SRC, despite loss of E-cadherin (epithelial
marker) and strong expression of Vimentin (mesenchymal
cell marker; see FIG. 6), are presumably epithelial and not
mesenchymal tumors that could be derived from an adenos
quamous component by epithelial-mesenchymal transition
(Cardiff R D, et al., The Mouse in Biomedical Research.
(2007), Volume II. Diseases, Second ed., eds. Fox JG et al.,
(Elsevier, New York), pp. 581-622).
Since the exact stages in the developmental progression
from stem cells to differentiated luminal and myoepithelial
cells remain largely undefined, a likely scenario accounting
for the Kras tumor heterogeneity in conjunction with the
hypothesis described above, is parallel transformation of
three different cell types. There are three reasons for such a
scenario. First, the originator of the Dunn A/B tumors is a
fully committed luminal-type cell that can still respond to
oncogenic stimuli without becoming apoptotic. Second, the
Wap gene, and therefore cre, is expressed in bipotentalveolar
progenitor cells of virgin and parous mice (Booth BW, et al.,
JCell Physiol. (2007), 212:729-736: Matulka LA, et al., Dev.
Biol. (2007), 303:29-44), and also that a significant expansion

of the Cd24"/Cd49' compartment containing mammary
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bipotent progenitors/stem cells (Shackleton M, et al., Nature
(2006), 439:84-88) occurs in Kras mice, it is speculated that
the squamous cell carcinoma probably originates from Such
cell precursors. Squamous metaplasia has been widely
reported in mouse models of breast cancer, including MMTV- 5
Wnt mice, in which progenitor cells are thought to be the
target of oncogenic transformation (Li Y., et al., Proc. Natl.
Acad. Sci. USA (2003), 100:15853-15858). In the context of
this scheme, to account for Gata3 expression and the presence
of a distinct CIS, it is proposed that a third cellof-origin, also 10
bearing the CD24 and CD49f markers, gives rise to pale cell
carcinoma.
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TABLE 10
Drug treatments
Mice

Glands

Tumor volume

Mouse Tumors

(n)

(n)

per gland (mm)

Vehicle
NB3
NB6

9
4
4

29
15
13

243.3
20.9
2.1

68.9
10.8
1.O

%

Pb

1OO
6.5
O.9

<O.OOO1
<O.OOO1

Mean S.E.M.

Because of data skewness, in tumor volume comparisons between the drug treatments and

the control (vehicle), probabilities (P) were calculated using Student's t-test after logarith
mic transformation of the values to meet the distribution criterion of the test.

If, on the basis of the new control data, the previous “9%
tumor volume in comparison with the control” for PPP
(7.3%) is normalized, it becomes 6.5%, i.e. NB3 has the same
potency as PPP. Importantly, however, NB6 (compound 21)
Efficacy of Compounds 18 and 21 to Ameliorate
appears to be 7 times more potent.
Kras-induced Mammory Carcinomas
While the invention has been described with respect to
specific examples including presently preferred modes of
The efficacy of compounds 18 “(NB3)' and 21 “(NB6) to 20 carrying out the invention, those skilled in the art will appre
ameliorate Kras-induced mouse mammary carcinomas was ciate that there are numerous variations and permutations of
tested. While testing NB3 and NB6 (4 mice each), 2 controls the above described systems and techniques that fall within
were added (2 tumor-bearing mice treated with vehicle). The the spirit and scope of the invention.
control data were pooled with the previous, and the new
Various publications are cited above, the contents of which
results are listed in Table 10:
are hereby incorporated by reference in their entireties.
11. EXAMPLE 6
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SEQUENCE LISTING
<16 Os NUMBER OF SEO ID NOS: 4
<210 SEQ ID NO 1
<211 LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<22 Os FEATURE;
<223> OTHER INFORMATION: Combined DNA/RNA

molecule: siRNA duplex R4

sense Strand
FEATURE;
OTHER INFORMATION:

siRNA duplex R4 sense strand

<4 OOs SEQUENCE: 1

caalugaguac aaculacc.gct t

21

SEO ID NO 2
LENGTH: 21
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE;

OTHER INFORMATION: Combined DNA/RNA molecule: siRNA duplex R4
antisense strand
FEATURE;
OTHER INFORMATION:

siRNA duplex R4 antisense strand

<4 OOs SEQUENCE: 2

gcggulaguug uacucaulugt t

21

SEO ID NO 3
LENGTH: 21
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE;

OTHER INFORMATION: Combined DNA/RNA molecule:
duplex Scra sense strand
<22 Os FEATURE;
<223> OTHER INFORMATION:

scrambled control

scrambled control duplex Scra sense strand

<4 OOs SEQUENCE: 3

glucacaccga ulaagucacat t

21
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- Continued

<210s, SEQ ID NO 4
&211s LENGTH: 21
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: Combined DNA/RNA molecule:
duplex Scra antisense strand

scrambled control

22 Os. FEATURE:

<223> OTHER INFORMATION: scrambled control duplex Scra antisense strand
<4 OOs, SEQUENCE: 4

ugugacuulau cqgugugact t

21

We claim:

-continued

1. A compound of formula I:
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wherein X, X, Y, Y and Z are independently hydrogen, a
C-Cs alkyl, or C-C alkoxy group with the proviso that
when X and X’ are H. Y.Y., and Z cannot all be OCH.
2. The compound of claim 1 wherein X, X', Y.Y. and Z are
hydrogen, methyl, or methoxy.
3. The compound of claim 1 wherein
X, X, Y, Y-H, and Z=OCH:
X, X, Y, Z=H, and Y=OCH:
X, X', Y—H, and Y, Z=OCH:
X, X, Z=H, and Y.Y—OCH; or
X, X,Y, Y-H, and Z=CH,
4. A compound selected from the group consisting of

d

OMe
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OMe
OH
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MeO
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OMe

8.

OMe

5. The compound of claim 1 wherein the C-C alkoxy is a
C-C alkoxy.
6. A pharmaceutical composition comprising a compound
of claim 1 and a pharmaceutically acceptable carrier thereof.
7. A pharmaceutical composition comprising a compound
of claim 2 and a pharmaceutically acceptable carrier thereof.
8. A pharmaceutical composition comprising a compound
of claim 3 and a pharmaceutically acceptable carrier thereof.
9. A pharmaceutical composition comprising a compound
of claim 4 and a pharmaceutically acceptable carrier thereof.
10. A pharmaceutical composition comprising a com
pound of claim 5 and a pharmaceutically acceptable carrier
thereof.

